# High number of SARS-CoV-2 persistent infections 1 uncovered through genetic analysis of samples from a 2 large community-based surveillance study 3

4

Mahan Ghafari<sup>\*,1,2</sup>, Matthew Hall<sup>1</sup>, Tanya Golubchik<sup>1,3</sup>, Daniel Ayoubkhani<sup>4,5</sup>, Thomas 5 House<sup>6</sup>, George MacIntyre-Cockett<sup>1,7</sup>, Helen Fryer<sup>1</sup>, Laura Thomson<sup>1</sup>, Anel Nurtay<sup>1</sup>, David 6 Buck<sup>7</sup>, Angie Green<sup>7</sup>, Amy Trebes<sup>7</sup>, Paolo Piazza<sup>7</sup>, Lorne J Lonie<sup>7</sup>, Ruth Studley<sup>4</sup>, Emma 7 Rourke<sup>4</sup>, Darren Smith<sup>8,9</sup>, Matthew Bashton<sup>8,9</sup>, Andrew Nelson<sup>9</sup>, Matthew Crown<sup>8,9</sup>, Clare 8 McCann<sup>9</sup>, Gregory R Young<sup>8,9</sup>, Rui Andre Nunes dos Santos<sup>9</sup>, Zack Richards<sup>9</sup>, Adnan 9 10 Tariq<sup>9</sup>, Roberto Cahuantzi<sup>4</sup>, Wellcome Sanger Institute COVID-19 Surveillance Team<sup>\*\*</sup>, 11 COVID-19 Infection Survey Group, The COVID-19 Genomics UK (COG-UK) Consortium<sup>++,10</sup>, Jeff Barrett<sup>11</sup>, Christophe Fraser<sup>1,7,11</sup>, David Bonsall<sup>1,7,16</sup>, Ann Sarah Walker<sup>12,13,14,15</sup>, Katrina 12 Lythqoe<sup>1,2</sup> 13

14

15 \*Corresponding author: mahan.ghafari@ndm.ox.ac.uk

16

17 <sup>1</sup>Big Data Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Oxford 18 OX3 7LF, UK.

19 <sup>2</sup>Department of Biology, University of Oxford, Oxford OX1 3SZ, UK

20 <sup>3</sup>Sydney Infectious Diseases Institute (Sydney ID), School of Medical Sciences, Faculty of

- 21 <sup>4</sup>Office for National Statistics, Newport, UK
- 22 Medicine and Health, University of Sydney

23 <sup>5</sup>Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, 24 UK

25 <sup>6</sup>Department of Mathematics, University of Manchester, Manchester, M13 9PL, UK

26 <sup>7</sup>Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Biomedical Research 27 Centre, University of Oxford, Old Road Campus, Oxford OX3 7BN, UK.

28 <sup>8</sup>The Hub for Biotechnology in the Built Environment, Department of Applied Sciences, Faculty of

29 Health and Life Sciences, Northumbria University, Newcastle upon Tyne, NE1 8ST, UK

- 30 <sup>9</sup>Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University,
- 31 Newcastle upon Tyne, NE1 8ST, UK
- 32 <sup>10</sup>https://www.cogconsortium.uk
- 33 <sup>11</sup>Wellcome Sanger Institute, Cambridge CB10 1SA, UK
- 34 <sup>12</sup>Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 35 <sup>13</sup>The National Institute for Health Research Health Protection Research Unit in Healthcare
- 36 Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.
- 37 <sup>14</sup>The National Institute for Health Research Oxford Biomedical Research Centre, University of
- 38 Oxford, Oxford, UK
- 39 <sup>15</sup>MRC Clinical Trials Unit at UCL, UCL, London, UK
- 40 <sup>16</sup>Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headington, Oxford
- 41 OX3 9DU, UK
- 42

43 \*\*The full list of names is available at https://www.sanger.ac.uk/project/wellcome-sanger-institute-

- 44 covid-19-surveillance-team/
- 45 \*\*The full list of names and affiliations of COG-UK members is provided in the appendix

#### Abstract 46

# 47

Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 48

infections may act as viral reservoirs that could seed future outbreaks <sup>1–5</sup>, give rise to 49

highly divergent lineages <sup>6–8</sup>, and contribute to cases with post-acute Coronavirus 50

disease 2019 (COVID-19) sequelae (Long Covid) <sup>9,10</sup>. However, the population 51

52 prevalence of persistent infections, their viral load kinetics, and evolutionary

dynamics over the course of infections remain largely unknown. We identified 381 53

infections lasting at least 30 days, of which 54 lasted at least 60 days. These 54

persistently infected individuals had more than 50% higher odds of self-reporting 55

56 Long Covid compared to the infected controls, and we estimate that 0.09-0.5% of

SARS-CoV-2 infections can become persistent and last for at least 60 days. In 57

nearly 70% of the persistent infections we identified, there were long periods during 58 which there were no consensus changes in virus sequences, consistent with

59 60 prolonged presence of non-replicating virus. Our findings also suggest reinfections

61 with the same major lineage are rare and that many persistent infections are

62 characterised by relapsing viral load dynamics. Furthermore, we found a strong

signal for positive selection during persistent infections, with multiple amino acid 63

64 substitutions in the Spike and ORF1ab genes emerging independently in different

65 individuals, including mutations that are lineage-defining for SARS-CoV-2 variants, at

target sites for several monoclonal antibodies, and commonly found in 66

immunocompromised patients <sup>11–14</sup>. This work has significant implications for 67

understanding and characterising SARS-CoV-2 infection, epidemiology, and 68

69 evolution.

70

# 71 Main

72

73 The emergence of highly divergent variants of SARS-CoV-2 has been a defining feature of the COVID-19 pandemic. While the evolutionary origins of these variants 74 75 are still a matter of speculation, multiple pieces of evidence point to chronic persistent infections as their most likely source <sup>5,7,15</sup>. In particular, infections in 76 immunocompromised patients who cannot clear the virus may lead to persistence for 77 months <sup>6,7,16,17</sup> or even years <sup>8,18</sup> before potentially seeding new outbreaks in the 78 community <sup>3</sup>. Persistence of SARS-CoV-2 during chronic infections exposes the viral 79 80 population to host-immune responses and other selective pressures as a result of treatments over prolonged periods of time. They also release the virus from 81 undergoing the tight population bottlenecks that are characteristic of SARS-CoV-2 82 transmission <sup>19,20</sup>, making the viral population less vulnerable to stochastic genetic 83 drift. These adaptive intrahost changes can lead to elevated evolutionary rates, 84 particularly in key regions of the Spike protein that are often associated with immune 85 escape and elevated rates of transmission <sup>13,14</sup>. 86

87

Despite the significant public health implications of persistent infections, uncertainty 88

still surrounds how common these infections are among the general population, how 89

90 long they last, their potential for adaptive evolution, and their contribution to Long 91 Covid.

92

In this work, we leveraged genetic, symptom, and epidemiological data from the 93

Office for National Statistics Covid Infection Survey (ONS-CIS)<sup>21</sup>, an ongoing large 94

- 95 scale community-based surveillance study carried out in the UK. We identified
- 96 individuals with persistent SARS-CoV-2 infection and characterised various aspects
- 97 of their infection including evolutionary changes in the virus, viral load kinetics,
- 98 number of reported symptoms, and prevalence of Long Covid.
- 99

# 100 Identifying persistent infections

101

102 We considered more than 100,000 high-quality sequenced samples from the ONS-

CIS collected between 2nd November 2020 to 15th August 2022, and representing 103

~95,000 people living in ~75,000 households across the UK (see Methods). 104

- Individuals in the survey were typically sampled once a week for the first four weeks 105
- 106 of their enrolment, and then monthly thereafter. To identify persistent infections we

107 first limited the dataset to individuals with two or more RT-PCR positive samples with

108 cycle threshold (Ct) values  $\leq$  30 (in which sequencing was attempted; a proxy for viral

- 109 load), taken at least 26 days apart, and where the consensus sequences were of the
- 110 same major lineages of Alpha, Delta, BA.1 or BA.2 (BA.4 and BA.5 not considered).
- 111 If those sequences also shared the same rare single nucleotide polymorphisms
- (SNPs) at one or more sites relative to the major-lineage population-level consensus, 112
- 113 we classified them as having a persistent infection.
- 114

115 We defined a rare mutation as one observed in 400 or fewer samples within the 116 entire ONS-CIS dataset, giving a false positive rate of identifying persistent infections 117 of 0-3% depending on the major lineage (see Methods and Supplementary Figure 118 1). We note that the rare SNP method provides a conservative estimate for the true 119 number of persistent infections since some persistent infections may not have rare 120 mutations. To further evaluate the robustness of our method in identifying persistent 121 infections, we considered the phylogenetic relationship between the sequences from persistent infections relative to other sequences of the same major lineage that 122 123 belonged to individuals with only a single sequence within the ONS-CIS dataset. The great majority of sets of sequences identified as belonging to the same persistent 124 infection formed monophyletic groups with strong bootstrap support (Figure 1a; see 125 126 also Supplementary Figure 2). However, seven sequences did not group with the other sequence(s) from the same persistent infection. All of these had high Ct values 127 128 (Ct~30) and poor genome coverage which may explain their lack of clustering on the 129 phylogeny (Supplementary Figure 2).

130

We found 381 persistent infections with sequences spanning at least 26 days, of 131

- which 54 spanned at least 56 days, representing nearly 0.07% (54/77,561) of all 132
- 133 individuals with one or more sequences (with Ct≤30) of the four major lineages we

134 investigated in this study (Figure 1b; see also Table 1). Notably, 9% (2/23), 9% (19/219), and 8% (8/208) of sequences from persistent infections with Alpha, Delta, 135 and BA.1, respectively, were sampled weeks after when the corresponding major 136 lineage has dropped to  $\leq 1\%$  frequency of all the ONS-CIS sequences (**Figure 1c**): 137 138 the longest infection was with BA.1 and lasted for at least 193 days (see Figure 1b). 139 The actual duration of persistent infections are likely to be at least 3-4 days longer 140 141 than the time between when the first and last sequenced samples were collected, since it typically takes 3-4 days since the start of infection for viral loads to be 142 sufficiently high to be sequenced (Ct $\leq$ 30) <sup>22,23</sup>, and similarly viral loads will be too low 143 (Ct values too high) to sequence at the tail end of infection. Since individuals were 144 typically sampled weekly during the first four weeks of enrollment, followed by 145 monthly sampling thereafter, it is unsurprising that most persistent infections had 146

- 147 observable durations clustering around 30 or 60 days (see Supplementary Figure 148 3).
- 149

150 We found evidence suggestive of transmission from 11 persistently infected 151 individuals: we identified two households each with two members having concurrent persistent infections, and in nine other households, one member tested positive for 152 153 SARS-CoV-2 by RT-PCR within 10 days of a positive sequenced sample being collected from a persistently infected individual from the same household. As well as 154 being clustered in households, the sequences from the suspected persistently 155 infected source and the recipient had either no consensus nucleotide differences 156 157 (nine cases) or one consensus nucleotide difference (two cases), consistent with transmission. If these do represent transmission, it is worth noting that none of these 158 159 persistent infections involved highly divergent sequences relative to their first sequence, and hence these do not provide an example of the emergence and 160 161 spread of highly divergent lineages.

- 162
- Identifying reinfections with the same major lineage 163
- 164

We considered a pair of sequences from the same individual to indicate a reinfection 165 if they were sampled at least 26 days apart, had at least one consensus nucleotide 166 167 difference between the sequenced sampling timepoints, and shared no rare SNPs (see **Methods**). This criterion may overestimate the true number of reinfections as 168 some persistent infections may not have a rare SNP, and within-host evolution can 169 170 lead to the loss of a rare SNP and/or the gain of other mutations leading to differences in the consensus sequence between the samples. We identified three 171 172 individuals for which pairs of sequences from different sampling timepoints had no 173 identical rare SNPs and at least one consensus difference, but whose viral load 174 trajectories were consistent with a persistent chronic infection. We therefore 175 excluded these individuals from the reinfection group (see Supplementary Figure 176 **4**).

178 Overall, we identified 60 reinfections with the same major lineage (Table 1). Of all 179 the cases classed as either persistent infections or reinfections with the same major lineage, 10-15% were classed as reinfections (see **Table 1**), rising to 20-40% if only 180 samples collected at least 56 days apart were included (see Figure 1b). This 181 182 suggests the number of individuals reinfected with the same major lineage is low 183 compared to the number of individuals with persistent infection. Sequences from individuals identified as reinfected, collected at the point of primary infection and 184 185 reinfection, did not form monophyletic groups and mostly belonged to distantly related subclades, and hence supports our method for identifying reinfections 186 (Figure 1a; Supplementary Figure 2). 187 188 Evidence of non-replicating virus during infection 189 190

191 Of the 381 persistently infected individuals that we identified, nearly 70% (267/381) had a pair of sequenced samples taken at least 26 days apart with no nucleotide 192 differences at the consensus level. This is striking given the between-host within-193 194 lineage evolutionary rate of SARS-CoV-2 of ~2 single nucleotide variants (SNVs) per 195 month <sup>24–26</sup>. We contrasted the number of consensus nucleotide differences between pairs of samples from persistent infections with 16,000 random pairs of sequences 196 197 sampled from the complete set of sequenced samples from the ONS-CIS, and with 198 each pair from the same major lineage (Supplementary Figure 5). Of these, only 6 pairs had no SNVs (i.e., less than 0.04% of pairs). 199

200

# 201 Emergence of notable mutations

202

203 For all pairs of sequences from each of the persistent infections, we identified 204 mutations for which there was a change in consensus between the two sampling 205 time points. Among the 381 persistently infected individuals, we observed 317 206 changes in the consensus nucleotide representing 277 unique mutations, and 31 deletions representing 18 unique deletions. Many of these mutations have previously 207 208 been identified as either lineage-defining mutations for variants of concern or variants of interest <sup>27</sup> (eight mutations and two deletions), recurrent mutations in 209 immunocompromised individuals <sup>12–14</sup> (15 mutations and four deletions), or key 210 mutations with antibody escape properties and target sites for various different 211 monoclonal antibodies <sup>11,28</sup> (seven mutations) (**Supplementary Table 1**). 212 213

214 We observed several mutations at the same genomic positions in multiple individuals

over the course of their persistent infections. For example, three BA.2 infected 215

216 individuals from different households acquired a mutation at codon position 547 in

217 Spike (Figure 2), two of which were the T547K mutation which is a lineage-defining

mutation for BA.1, and one the K547T mutation (Figure 2c; also see 218

Supplementary Table 1). Strikingly, twelve individuals acquired a deletion 219

(ORF1ab:  $\Delta$ 81-87) in the NSP1 coding region. A similar deletion has previously been 220

221 observed during the chronic infection of an immunocompromised individual with

222 cancer <sup>16</sup>, and was associated with lower type I interferon response in infected cells 223 <sup>29</sup>. We also identified a persistent infection with BA.1 lasting for at least 133 days 224 during which 33 unique mutations (23 mutations in ORF1ab, 6 in Spike, 1 in ORF3a, 1 in M, and 2 in ORF7) were observed (see **Supplementary Figure 2**); eleven of the 225 226 ORF1ab mutations and all of the mutations in Spike, ORF3a, and ORF7 were

- 227 nonsynonymous.
- 228

229 Overall, we observed a strong signal for positive selection in Spike, with nearly ninefold more nonsynonymous compared to synonymous mutations (Figure 2b). With a 230 total of seven nonsynonymous mutations, ORF8 had the highest per base number of 231 232 nonsynonymous mutations followed by Spike with 61 nonsynonymous mutations.

233

# 234 Persistence with relapsing viral load

235 Of the 381 persistent infections, 65 had three or more RT-PCR tests taken over the 236 237 course of their infection. We classified these infections as persistent-relapsing if they 238 had a negative RT-PCR test during the infection (n=20), and the rest as persistent-239 chronic (n=45) (**Figure 3a,b**). Given the weekly or monthly sampling of individuals 240 enrolled in the ONS-CIS, infections classed as persistent-chronic may have 241 unsampled periods of very low viral burden, meaning the persistent-relapsing 242 category is likely to be an underestimate. Nonetheless, the observation of relapsing 243 viral load dynamics in over 30% of cases is striking given that, in the absence of genetic information, they could have been misidentified as reinfections, depending 244 245 on the definition used. Of the 27 cases identified as reinfections with three or more 246 RT-PCR tests, all showed relapsing viral load dynamics (Figure 3c).

247

248 As the sampling strategy of ONS-CIS is based on testing representative individuals 249 across the UK regardless of symptoms, we can estimate the percentage of SARS-250 CoV-2 infections that are persistent and last for longer than 60 days in the general 251 population. This requires making assumptions about how many persistent infections 252 are missed among ONS-CIS participants due to the monthly (and weekly) sampling. More precisely, estimating the proportion of infections that are persistent depends on 253 the proportion of days the infection has sequenceable virus during the infection 254 255 (would have Ct≤30 if tested); the fewer the number of days the infection has 256 sequenceable virus, the more likely it is that a persistent infection is be missed. By taking two extreme scenarios for the proportion of days that the virus is 257 258 sequenceable during persistent infection (0.7 and 0.14; see Methods), we estimate that approximately 0.1-0.5% of infections become persistent for 60 days or more. 259

260

261 Difference in viral load and symptoms

262

For the majority of persistent infections, Ct values (inversely proportional to viral titre 263

<sup>30</sup>) were higher at the last sequenced time point compared to the first sequenced 264

265 time point (Figure 3d). For reinfections with the same major lineage, the last

- 266 sequenced sample also had higher Ct values than the first, but the magnitude of the
- difference was smaller compared to persistent infections (Figure 2d). In both cases, 267
- the rise in Ct value (decrease in viral titre) during infections or between reinfections 268
- could be a consequence of host immunity or within-host compartmentalisation. 269
- 270 Additionally, the rise in Ct for reinfections could be due to the disproportionate
- 271 sampling of individuals with older infections, which tend to have lower viral loads,
- towards the end of an epidemic wave <sup>31,32</sup>. 272
- 273
- Individuals with persistent infections remained largely asymptomatic during the later 274 stages of infection, with, on average, reporting two fewer symptoms in the last 7 275 days at the last time of sampling (at which a sequence was obtained) when 276 compared to the first. They also consistently reported very few or no symptoms after 277 278 the first positive sample (Figure 3e). In comparison, individuals reinfected with the 279 same major lineage reported on average only one fewer symptom at the reinfection
- sampling time point compared to the primary sampling time point (Figure 3e). 280
- 281
- Prevalence of Long Covid 282
- 283

From February 2021, as well as reporting symptoms, participants were asked if they 284 describe themselves as having Long Covid and still experiencing symptoms more 285 than four weeks after they first had COVID-19 (see Methods). We estimated the 286 287 prevalence of self-reported Long Covid in the persistently infected individuals compared with a control group, accounting for several confounding variables (see 288 289 Methods). In the persistent infection group, 9.0% of respondents (32/354) selfreported Long Covid at their first visit ≥12 weeks since the start of infection, and 290 291 7.1% (19/266) reported Long Covid at  $\geq$ 26 weeks. However, in the control group, 292 only 5.1% (4,976/97,404) reported Long Covid at their first visit  $\geq$ 12 weeks, and 4.5% 293 (3,261/72,407) reported Long Covid at  $\geq 26$  weeks.

294

Correcting for confounders, we found strong evidence for a 55% higher odds of 295 296 reporting Long Covid ≥12 weeks post-infection among persistently infected individuals compared to controls (Chi square test with Yates correction <sup>33</sup> p=0.004 for 297 the unadjusted model, p=0.021 for the adjusted model), but no evidence of a 298 299 difference for Long Covid ≥26 weeks post-infection (p=0.127 for the unadjusted model, p=0.367 for the adjusted model) (Table 2). The lower rate of reporting Long 300 Covid 26 weeks post-infection could be because the majority of the persistent 301 302 infections we identified lasted for less than 26 weeks, and hence persistence of an infection may no longer be a contributing factor to Long Covid. 303 304

- 305 Discussion
- 306

We developed a robust approach for identifying persistent SARS-CoV-2 infections in 307

- individuals with sequenced samples spanning a month or longer. Of the 381 308
- 309 persistent infections we identified among participants of the ONS-CIS, 54 lasted at

310 least two months, two over six months, and in some cases the infecting lineage had gone extinct in the general population. In contrast, we only identified 60 reinfections 311 by the same major lineage as the primary infection, suggesting immunity to the same 312 variant remains strong after infection, at least until the lineage has gone extinct. 313

314

315 The large number of persistent infections we uncovered is striking, given the leading hypothesis that many of the variants of concern (VOCs) emerged wholly or partially 316 317 during long-term chronic infections in immunocompromised individuals <sup>1</sup>. Since the 318 ONS-CIS is a community-based surveillance study, our observations suggest the pool of people in which long-term infections could occur, and hence potential 319 320 sources of divergent variants, may be much larger than generally thought. We 321 estimate that more than nearly one in a thousand of all infections, and potentially as 322 many as one in 200, may become persistent for at least two months. The harbouring 323 of these persistent infections in the general community may also help explain the early detection of cryptic lineages circulating in wastewaters <sup>34,35</sup> long before they 324

- 325 spread in the population at large.
- 326

327 In support of the hypothesis that VOCs may emerge during prolonged infections, a 328 number of studies have shown elevated evolutionary rates driven by selection during chronic infections of immunocompromised individuals <sup>6–8</sup>. Among the persistently 329 330 infected individuals we identified, we also found strong evidence for positive 331 selection and parallel evolution, particularly in Spike and ORF1ab. In the most extreme case, we observed one persistent infection with 33 substitutions over a four-332 333 month period, 20 of which were nonsynonymous.

334

335 Potentially more remarkable, however, was our discovery of viral infections exhibiting 336 latent evolutionary dynamics, with no consensus level genome changes for two 337 months or longer. As far as we are aware, this is the first study to demonstrate that 338 decelerated evolutionary rates may be a common outcome of persistent infection. The factors causing these low rates of evolution are unknown, but one possible 339 explanation is infection of long-lived cells <sup>36,37</sup> which then seed new outbreaks within 340 the infected individual weeks or months later. Although the relapsing viral load 341 dynamics we found in many of the persistently infected individuals supports this 342 hypothesis, we did not find any consistent pattern between the amount of viral 343 divergence during infection and the lower viral load activity in these individuals. 344 345 Intriguingly, individuals with persistent infections report fewer symptoms later in a 346 persistent infection compared to at their first positive sample, or remain 347

348 asymptomatic throughout infection, but have more than 50% higher odds of Long

Covid compared to a control group. Although the link between viral persistence and 349

Long Covid may not be causal, these results suggest persistent infections could be 350 contributing to the pathophysiology of Long Covid <sup>10,38</sup>, as also evidenced by the 351

observation of circulating SARS-CoV-2 S1 spike protein in a subset of patients with 352

Long Covid months after first infection <sup>39</sup>. The association between persistent 353

infection and Long Covid does not imply that every persistent infection can lead to

Long Covid, only 9% of persistently infected individuals reported having Long Covid, 355 nor does it mean that all cases of Long Covid are due to a persistent infection. 356 Indeed, many other possible mechanisms have been suggested to contribute to 357 358 Long Covid including autoimmunity/inflammation, organ damage, EBV reactivation, 359 and micro thrombosis (see ref <sup>10</sup> for a recent review). 360 361 Taken together, our observations highlight the continuing importance of communitybased genomic surveillance both to monitor the emergence and spread of new 362 variants, but also to gain a fundamental understanding of the natural history and 363 evolution of novel pathogens and their clinical implications for patients. 364

365 366

354

367 **Methods** 

368

# **ONS COVID-19 Infection Survey** 369

370

371 The ONS-CIS is a UK household-based surveillance study in which participant 372 households are approached at random from address lists across the country to 373 provide a representative sample of the population <sup>40</sup>. All individuals aged two years 374 and older from each household who provide written informed consent provide swab 375 samples (taken by the participant or parent/carer for those under 12 years). regardless of symptoms, and complete a guestionnaire at assessments, which occur 376 377 weekly for the first month in the survey and then monthly. From 26 April 2020 to 31 July 2022, assessments were conducted by study workers visiting each household; 378 379 from 14 July 2022 onwards assessments were remote, with swabs taken using kits 380 posted to participants and returned by post or courier, and questionnaires completed 381 online or by telephone. Positive swab samples with Ct≤30 were sent for sequencing 382 (see below). For this analysis, we included data from 2nd November 2020 to 15th August 2022, spanning a period from the earliest Alpha to latest Omicron BA.2 383 384 sequences within the ONS-CIS dataset.

385

386 This work contains statistical data from ONS which is Crown Copyright. The use of the ONS statistical data in this work does not imply the endorsement of the ONS in 387 388 relation to the interpretation or analysis of the statistical data. This work uses 389 research datasets which may not exactly reproduce National Statistics aggregates.

- 390
- Sequencing 391

392

393 From December 2020 onwards sequencing was attempted on all positive samples with Ct≤30; before this date, sequencing was attempted in real-time wherever 394 possible, with some additional retrospective sequencing of stored samples. The vast 395

majority of samples were sequenced on Illumina Novaseq, with a small number 396

397 using Oxford Nanopore GridION or MINION. One of two protocols were used: either

the ARTIC amplicon protocol <sup>41</sup> with consensus FASTA sequence files generated 398 399 using the ARTIC nextflow processing pipeline <sup>42</sup>, or veSeq, an RNASeq protocol based on a quantitative targeted enrichment strategy <sup>19,43</sup> with consensus sequences 400 produced using *shiver*<sup>44</sup>. During our study period, we identified 94,943 individuals 401 402 with a single sequence and 5,774 individuals with two or more sequences. Here, we 403 only included sequences with  $\geq$ 50% genome coverage. 404

405 Identifying rare SNPs

406

An important criterion for determining whether two sequences from the same 407 408 individual are from the same infection is whether they share a rare single nucleotide polymorphism (SNP). These are defined as SNPs that are shared by fewer than 400 409 sequences corresponding to each major lineage within the full ONS-CIS dataset 410 411 (Supplementary Figure 1). The thresholds were chosen to maximise the number of persistent infections identified whilst minimising the number of false positives (see 412 below). The major lineages we considered were Alpha (B.1.1.7), Delta (B.1.617.2), 413 414 Omicron BA.1 and Omicron BA.2, including their sublineages. Approximately 92-415 98% of all sequences from the four major lineages had a rare SNP relative to the

- 416 major-lineage population-level consensus.
- 417
- 418 Identifying reinfections with the same major lineage
- 419

Any pair of sequences from the same individual, of the same major lineage, and at 420 421 least 26 days apart were considered as candidate reinfections. Of these, pairs that 422 had at least one nucleotide difference at the consensus level, and did not share any 423 rare SNPs, were classed as reinfections. Pairs that had no identical rare SNPs, nor 424 any nucleotide differences at the consensus level, were classed as undetermined.

- 425
- 426 Identifying individuals with persistent infection
- 427

428 We first identified individuals with two or more sequenced samples taken at least 26 429 days apart. We chose this cutoff because the majority of acutely infected individuals shed the virus for <20 days and no longer than 30 days in the respiratory tract  $^{23,45}$ . 430 431 Given the extreme heterogeneity in the shedding profiles during some acute infections <sup>23</sup>, we also considered a more conservative 56-day cutoff for some 432 433 analyses. 434 For each identified individual we calculated the number of consensus nucleotide 435 436 differences per site for all within-individual pairwise combinations of samples

437 (Supplementary Figure 6). Only sites where a nucleotide difference could be called were included. 438

- 439
- Candidate persistent infections were defined in one of two ways: (1) pairs of 440
- 441 sequenced samples that belonged to the same major lineage, and (2) pairs of

442 sequenced samples where one or both had no defined phylogenetic lineage, but where the genetic distance between them was lower than that required to 443 444 differentiate two major lineages (see **Supplementary Figure 6**). We assumed pairs belonging to different major lineages were either coinfections or reinfections with two 445 446 different virus lineages. Only candidate persistent infections were considered in 447 further analysis. 448 449 Among the pool of candidate persistent infections, we defined persistent infections as those with sequences sharing one or more rare SNPs at two or more consecutive 450 time points relative to the population-level consensus. A rare SNP is one that is 451 452 observed in 400 or fewer samples within the entire ONS-CIS dataset. 453 454 Determining the false positive rate for persistent infections 455 For each major lineage we generated a data set of 1,000 randomly paired 456 sequences from different individuals in the ONS-CIS, each sampled at least 26 days 457 458 apart. We determined the number of these pairs that would have been incorrectly 459 identified as persistent infections as a function of the threshold for determining if a SNP is rare (Supplementary Figure 1). Although the total number of persistent 460 infections identified grew as the threshold for determining if a SNP is rare increased, 461 462 at very high thresholds the rate of false positives was also high. In our study, we chose a threshold of 400 sequences (corresponding to all sequences of the same 463 major lineage within the full ONS-CIS dataset) for all of the major lineages, giving a 464 465 false positive rate (identifying an infection as persistent when it was not) of 0-3%. 466 467 Estimating the prevalence of persistent infections 468 469 Within the ONS-CIS we identified 54 infections that lasted 60 days or more. 470 Comparing this to the number of individuals that had sequenced samples belonging to Alpha, Delta, BA.1 or BA.2, which to a good approximation will be the number of 471 472 infections of these variants, we identified approximately 54/77,561 (0.07%) infections 473 as persistent for >= 60 days. Since the ONS-CIS is a representative sample of individuals from the general population, we can estimate the percentage of all SARS-474 475 CoV-2 infections that became persistent for two months or longer. At one extreme, if all persistent infections have sequenceable virus for only four days per month 476 (assuming viral dynamics similar to one acute infection each month), only 14% of 477 478 persistent infections would be detected through monthly sampling. Correcting for this, we would estimate the percentage of persistent infections in the general 479 480 population to be 0.5% (0.07% / 0.14). At the other extreme, if we assume all 481 persistent-chronic infections (70% of persistent infections; see Main text) are detectable through monthly sampling, and the rest have detectable virus for 4 days 482 per month, then we estimate that 74% (70% + 0.14\*30%) of persistent infections 483 were identified, giving an estimate of 0.09% (0.07% / 0.74) infections being 484 485 persistent in the general population.

486

### 487 Phylogenetic analysis

488

489 For each of the four major lineages, we chose 600 consensus sequences with at 490 least 95% coverage from the ONS-CIS dataset using weighted random sampling, 491 with each sample of major lineage *i* collected in week *j* given a weight  $1/n_{ij}$ , where  $n_{ij}$ is the number of sequences of major lineage *i* collected during week *j*<sup>25</sup>. These 492 493 sequences were added as a background set to the collection of all consensus 494 sequences for samples from persistent infections and reinfections. Mapping of each sequence to the Wuhan-Hu-1 reference sequence was already performed by *shiver* 495 496 and thus a full alignment for each of the four lineages could be constructed using 497 only this.

498

Maximum likelihood phylogenetic trees were constructed using IQ-TREE 1.6.12<sup>46</sup> 499 using the GTR+gamma substitution model and the ultrafast bootstrap <sup>47</sup>. Each tree 500 501 was rooted using the collection dates of the samples and the heuristic residual mean 502 square algorithm in TempEst <sup>48</sup>. Visualisation used ggtree <sup>49</sup>.

503

# 504 Comparing viral load activities and symptoms

505

506 To quantify the changes in viral load activities during persistent infections, we compared Ct values at the last time point a sequence was obtained to when the first 507 sequence was collected. Similarly, for reinfections, we compared the changes in Ct 508 509 value between the primary infection and reinfection. We used a paired t-test to calculate p-values in both cases as the distribution of differences in Ct values were 510 511 normally distributed for both persistent infections (W=0.99, p=0.28) and reinfections 512 (W=0.99, p=0.78) as determined by the Shapiro-Wilk test <sup>50</sup>.

513

We also tracked 12 symptoms consistently solicited from all participants at every 514 assessment. Symptoms were fever, weakness/tiredness, diarrhoea, shortness of 515 516 breath, headache, nausea/vomiting, sore throat, muscle ache, abdominal pain, cough, loss of smell, and loss of taste. At each follow-up assessment, participants 517 518 were asked whether these 12 symptoms had been present in the past seven days. Symptom discontinuation was defined as the first occurrence of two successive 519 520 follow-up visits without reporting symptoms. To compare symptom counts during persistent infections and reinfections, we used the paired Wilcoxon test as the 521 522 distribution of symptom differences is not normally distributed (see Figure 3d). 523

524 Long Covid analysis

525 From February 2021, at every assessment, participants were asked "would you 526 527 describe yourself as having Long Covid, that is, you are still experiencing symptoms more than 4 weeks after you first had COVID-19, that are not explained by 528 529 something else?". When estimating Long Covid prevalence in this analysis, we

530 considered the first assessment at least 12 weeks and at least 26 weeks after

infection. Our control group comprised all individuals with a positive PCR test and 531

- Ct≤30, excluding the persistently infected individuals identified in this study, over the 532
- same time span as persistent infections. We also ensured the follow-up from the 533 534 start of infection to first Long Covid response was similar between persistent
- 535 infections and controls (see Table 2).
- 536

537 In calculating the odds ratio of Long Covid in persistently infected individuals relative to the control group, we accounted for confounding variables such as age at the last 538 birthday, sex, Ct value, calendar date, area deprivation quintile group, presence of 539 540 self-reported long-term health conditions (binary), vaccination status (unvaccinated or single-vaccinated, fully-vaccinated or booster-vaccinated 14-89 days ago, fully-541 vaccinated or booster-vaccinated 90-179 days ago, fully-vaccinated or booster-542 543 vaccinated  $\geq$ 180 days ago), and days from first positive test to Long Covid follow-up response. All variables except the last one were defined at the time of the first 544 positive test. Continuous variables (age, Ct value, calendar date, days to follow-up 545 546 response) were modelled as restricted cubic splines with a single internal knot at the median of the distribution and boundary knots at the 5<sup>th</sup> and 95<sup>th</sup> percentiles. 547 Vaccination status was derived from a combination of CIS and NIMS data for 548 participants in England, and CIS data alone for participants in Wales, Scotland and 549 Northern Ireland. 550

551

We were unable to do the Long Covid analysis for the reinfection group due to the 552 553 low number of participants in this cohort who reported new-onset Long Covid ≥12 weeks or ≥26 weeks after infections. 554

- 555
- 556

# 557 **Funding Statement**

558

The CIS was funded by the Department of Health and Social Care and the UK 559 560 Health Security Agency with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish 561 Government. COG-UK is supported by funding from the Medical Research Council 562 (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health 563 Research (NIHR) (grant code: MC PC 19027), and Genome Research Limited, 564 operating as the Wellcome Sanger Institute. The authors acknowledge use of data 565 generated through the COVID-19 Genomics Programme funded by the Department 566 of Health and Social Care. ASW is supported by the National Institute for Health 567 568 Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership 569 with the UK Health Security Agency (UK HSA) (NIHR200915) and the NIHR Oxford 570 Biomedical Research Centre, and is an NIHR Senior Investigator. TH is supported 571 by the Royal Society and Alan Turing Institute for Data Science and Artificial 572 573 Intelligence. KAL is supported by the Royal Society and the Wellcome Trust

574 (107652/Z/15/Z). The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The views 575 expressed are those of the author(s) and not necessarily those of the NHS, the NIHR 576 or the Department of Health. The views expressed are those of the author and not 577 necessarily those of the Department of Health and Social Care or UKHSA. 578 579 580 Data and materials availability 581 All genomic data have been made publicly available as part of the COVID-19 582 Genomics UK (COG-UK) Consortium <sup>51</sup>. All other data, excluding personal clinical 583

information on participants, are available in the main text, supplementary materials, 584

or our GitHub repository (https://github.com/mg878/ONS-CIS analysis). 585

587 588	Re	ferences
589	1.	Dennehy, J. J., Gupta, R. K., Hanage, W. P., Johnson, M. C. & Peacock, T. P. Where is
590		the next SARS-CoV-2 variant of concern? Lancet 399, 1938–1939 (2022).
591	2.	Otto, S. P. et al. The origins and potential future of SARS-CoV-2 variants of concern in
592		the evolving COVID-19 pandemic. Curr. Biol. 31, R918–R929 (2021).
593	3.	Gonzalez-Reiche, A. S. et al. SARS-CoV-2 variants in the making: Sequential intrahost
594		evolution and forward transmissions in the context of persistent infections. medRxiv
595		2022.05.25.22275533 (2022) doi:10.1101/2022.05.25.22275533.
596	4.	Hill, V. et al. The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the
597		UK. Virus Evolution 8, veac080 (2022).
598	5.	Ghafari, M., Liu, Q., Dhillon, A., Katzourakis, A. & Weissman, D. B. Investigating the
599		evolutionary origins of the first three SARS-CoV-2 variants of concern. Frontiers in
600		Virology Section: Diversification and Evolution, (2022).
601	6.	Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised
602		Host. N. Engl. J. Med. 383, 2291–2293 (2020).
603	7.	Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature
604		<b>592</b> , 277–282 (2021).
605	8.	Chaguza, C. et al. Accelerated SARS-CoV-2 intrahost evolution leading to distinct
606		genotypes during chronic infection. <i>medRxiv</i> (2022) doi:10.1101/2022.06.29.22276868.
607	9.	Swank, Z. et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus
608		2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin. Infect.
609		<i>Dis.</i> ciac722 (2022) doi:10.1093/cid/ciac722.
610	10.	Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings,
611		mechanisms and recommendations. Nat. Rev. Microbiol. (2023) doi:10.1038/s41579-
612		022-00846-2.
613	11.	Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain
614		Reveals Constraints on Folding and ACE2 Binding. Cell 182, 1295–1310.e20 (2020).

- 12. McCarthy, K. R. *et al.* Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive
- 616 antibody escape. *Science* **371**, 1139–1142 (2021).
- 13. Harari, S. *et al.* Drivers of adaptive evolution during chronic SARS-CoV-2 infections.
- 618 *Nature Medicine* **28**, 1501–1508 (2022).
- 619 14. Wilkinson, S. A. J. *et al.* Recurrent SARS-CoV-2 mutations in immunodeficient patients.
- 620 *Virus Evol* **8**, veac050 (2022).
- 15. Rambaut, A. *et al.* Preliminary genomic characterisation of an emergent SARS-CoV-2
- 622 lineage in the UK defined by a novel set of spike mutations. *Virological*
- 623 https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-
- 624 lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563 (2020).
- 16. Avanzato, V. A. *et al.* Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an
- Asymptomatic Immunocompromised Individual with Cancer. *Cell* 183, 1901–1912.e9(2020).
- 628 17. Cele, S. *et al.* SARS-CoV-2 prolonged infection during advanced HIV disease evolves
  629 extensive immune escape. *Cell Host Microbe* **30**, 154–162.e5 (2022).
- 18. Nussenblatt, V. *et al.* Yearlong COVID-19 Infection Reveals Within-Host Evolution of
- 631 SARS-CoV-2 in a Patient With B-Cell Depletion. J. Infect. Dis. 225, 1118–1123 (2022).
- 632 19. Lythgoe, K. A. *et al.* SARS-CoV-2 within-host diversity and transmission. *Science* **372**,
  633 (2021).
- Braun, K. M. *et al.* Acute SARS-CoV-2 infections harbor limited within-host diversity and
  transmit via tight transmission bottlenecks. *PLoS Pathog.* **17**, e1009849 (2021).
- 636 21. Pouwels, K. B. *et al.* Community prevalence of SARS-CoV-2 in England from April to
- November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public Health* 6, e30–e38 (2021).
- 639 22. Kissler, S. M. et al. Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and
- 640 Unvaccinated Persons. *N. Engl. J. Med.* **385**, 2489–2491 (2021).
- 641 23. Jones, T. C. *et al.* Estimating infectiousness throughout SARS-CoV-2 infection course.
- 642 Science **373**, (2021).

- 643 24. Ghafari, M. et al. Purifying selection determines the short-term time dependency of
- 644 evolutionary rates in SARS-CoV-2 and pH1N1 influenza. Preprint at
- 645 https://doi.org/10.1101/2021.07.27.21261148.
- 646 25. Lythgoe, K. A. et al. Lineage replacement and evolution captured by the United
- 647 Kingdom Covid Infection Survey. *medRxiv* (2022) doi:10.1101/2022.01.05.21268323.
- 648 26. Neher, R. A. Contributions of adaptation and purifying selection to SARS-CoV-2
- 649 evolution. *Virus Evol* **8**, veac113 (2022).
- 650 27. Hodcroft, E. B. CoVariants: SARS-CoV-2 Mutations and Variants of Interest.
- 651 https://covariants.org/ (2021).
- 652 28. Cox, M. *et al.* SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro
  653 studies. *Nat. Rev. Microbiol.* 21, 112–124 (2023).
- 29. Lin, J.-W. *et al.* Genomic monitoring of SARS-CoV-2 uncovers an Nsp1 deletion variant
- 655 that modulates type I interferon response. *Cell Host Microbe* **29**, 489–502.e8 (2021).
- 30. Tom, M. R. & Mina, M. J. To Interpret the SARS-CoV-2 Test, Consider the Cycle
- 657 Threshold Value. *Clinical infectious diseases: an official publication of the Infectious*
- 658 *Diseases Society of America* vol. 71 2252–2254 (2020).
- 659 31. Hay, J. A. *et al.* Estimating epidemiologic dynamics from cross-sectional viral load
  660 distributions. *Science* 373, (2021).
- 32. Fryer, H. R. et al. Viral burdens are associated with age and viral variant in a population-
- 662 representative study of SARS-CoV-2 that accounts for time-since-infection related
- 663 sampling bias. Preprint at https://doi.org/10.1101/2022.12.02.518847 (2022).
- 33. Yates, F. Contingency tables involving small numbers and the χ 2 test. *Suppl. J. R. Stat.*Soc. 1, 217 (1934).
- 34. Karthikeyan, S. *et al.* Wastewater sequencing reveals early cryptic SARS-CoV-2 variant
  transmission. *Nature* 609, 101–108 (2022).
- 668 35. Shafer, M. M. *et al.* Tracing the origin of SARS-CoV-2 Omicron-like Spike sequences
- 669 detected in wastewater. *medRxiv* (2022) doi:10.1101/2022.10.28.22281553.
- 670 36. Lythgoe, K. A., Gardner, A., Pybus, O. G. & Grove, J. Short-Sighted Virus Evolution and

a Germline Hypothesis for Chronic Viral Infections. *Trends Microbiol.* **25**, 336–348

- 672 (2017).
- 37. Lythgoe, K. A., Lumley, S. F., Pellis, L., McKeating, J. A. & Matthews, P. C. Estimating
- hepatitis B virus cccDNA persistence in chronic infection. *Virus Evol* **7**, veaa063 (2021).
- 675 38. Marx, V. Scientists set out to connect the dots on long COVID. *Nat. Methods* **18**, 449–
- 676 453 (2021).
- 39. Schultheiß, C. *et al.* Liquid biomarkers of macrophage dysregulation and circulating
- spike protein illustrate the biological heterogeneity in patients with post-acute sequelae
- 679 of COVID-19. J. Med. Virol. **95**, e28364 (2023).
- 40. Pouwels, K. B. et al. Community prevalence of SARS-CoV-2 in England from April to
- November, 2020: results from the ONS Coronavirus Infection Survey. *Lancet Public Health* 6, e30–e38 (2021).
- 683 41. COG-UK. COG-UK publication. https://www.protocols.io/workspaces/coguk/publication
- 684 (2020).
- 685 42. Connor Lab. *ncov2019-artic-nf*. (Github).
- 43. Bonsall, D. *et al.* A Comprehensive Genomics Solution for HIV Surveillance and Clinical
  Monitoring in Low-Income Settings. *J. Clin. Microbiol.* 58, (2020).
- 44. Wymant, C. *et al.* Easy and accurate reconstruction of whole HIV genomes from shortread sequence data with shiver. *Virus Evol* **4**, vey007 (2018).
- 45. Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration
- of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe* 2, e13–e22 (2021).
- 46. Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic
  Inference in the Genomic Era. *Mol. Biol. Evol.* 37, 1530–1534 (2020).
- 47. Hoang, D. T., Chernomor, O., von Haeseler, A., Minh, B. Q. & Vinh, L. S. UFBoot2:
- 696 Improving the Ultrafast Bootstrap Approximation. *Mol. Biol. Evol.* **35**, 518–522 (2018).
- 48. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal
- 698 structure of heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus*

699 *Evol* **2**, vew007 (2016).

- 49. Yu, G., Smith, D. K. & Tsan-Yuk, Z. H. L. ggtree: an R package for visualization and
- annotation of phylogenetic trees with their covariates and other associated data.

702 *Methods in Ecology and Evolution* **8**, 28–36 (2017).

- 50. Shapiro, S. S. & Wilk, M. B. An Analysis of Variance Test for Normality (Complete
- 704 Samples). *Biometrika* **52**, 591–611 (1965).
- 51. COVID-19 Genomics UK (COG-UK) consortiumcontact@cogconsortium.uk. An
- integrated national scale SARS-CoV-2 genomic surveillance network. *Lancet Microbe* **1**,
- 707 e99–e100 (2020).

#### **Tables** 709

710

### Table 1: Frequency of persistent infections and reinfections per major lineage. 711

712

Major lineage	Reinfection >26 days	Reinfection >56 days	Persistent infection >26 days	Persistent infections >56 days	%Reinfection >26 days	%Reinfection >56 days
B.1.1.7	7	3	11	3	39%	50%
B.1.617.2	11	4	106	13	9%	24%
BA.1	14	2	97	15	13%	12%
BA.2	28	15	167	23	14%	40%

713

714

#### 715 Table 2: Prevalence of Long Covid in persistently infected individuals.

716

#### 717 Long Covid ≥12 weeks post-infection

Group	n	Long Covid	Median follow- up (IQR*)	Unadjusted OR† (95% Cl**)	Adjusted OR (95% Cl)
Exposed	356	32 (9.0%)	101 (91-113)	1.27 (1.19-2.47)	1.55 (1.07-2.25)
Control	78,902	4,291 (5.4%)	100 (91-115)	Reference	Reference

718

#### 719 Long Covid ≥26 weeks post-infection

Group	n	Long Covid	Median follow-	Unadjusted OR	Adjusted OR
			up (IQR)	(95% CI)	(95% CI)
Exposed	326	19 (5.8%)	312 (271-390)	1.44 (0.90-2.29)	1.24 (0.77-2.00)
Control	72,608	3,000 (4.1%)	320 (272-384)	Reference	Reference

# 720 \* IQR=interquartile range

721 **†OR=odds** ratio

722 \*\*CI=confidence interval

#### 723 **Figures**





725 726

727 Figure 1: Individuals identified with persistent infections and reinfections within the 728 ONS-CIS. (a) Phylogenetic relationship between samples from persistent infections and

729 reinfections with a representative background population of Alpha (see Supplementary 730 Figure 2 for the analysis on the other three major lineages). Dashed lines connect every pair 731 of sequences from the same individual. Pairs from persistent infections cluster closely 732 together while reinfections do not. All sequences from the same individual are given the 733 same colour. (b) Days between the earliest and latest genomic samples from persistent 734 infections and reinfections. Each point represents a single individual. Solid vertical lines 735 show the 26- and 56-day cutoffs. Numbers on the side of each box shows the total counts 736 per category for each major lineage. (c) Total number of sequences in the ONS-CIS per 737 major lineage over time. (d) Timing of persistent infections (black) during the UK epidemic. 738 Some persistent infections can be identified up to weeks after the lineage has been replaced

739 at the population level. The numbers on the side of each box shows the total sequence

740 counts for each category.



Gene	widtation	marviadais	Lineage of persistent intection	Description
Spike	T547K	2	BA.2	Lineage-defining for BA.1
Spike	L452R	2	BA.2	Lineage-defining for Delta, BA.4/5; recurrent in immunocompromised patients
Spike	T376A	2	BA.1	Lineage-defining for BA.2/4/5
Spike	T95I	1	BA.2	Lineage-defining for BA.1; recurrent in immunocompromised patients
Spike	G446V/D	2	B.1.617.2, BA.2	Target site for several monoclonal antibodies
Spike	D215G	1	BA.2	Lineage-defining for Beta
Spike	†ΔA243/L244	3	one B.1.1.7, two BA.2	Lineage-defining for Beta; recurrent in immunocompromised patients
Spike	ΔΥ144	1	BA.2	Lineage-defining for Alpha, BA.1 and Eta
ORF1ab	L5905F	2	BA.1, BA.2	Commonly found in Mu, Delta, and B.1.1.519
ORF1ab	T4175I	2	BA.1	Commonly found in BA.2
ORF1ab	T1638I	2	BA.2	Recurrent in immunocompromised patients
ORF1ab	D4532D	1	BA.2	Recurrent in immunocompromised patients
ORF1ab	Δ81-86	12	one B.1.617.2, three BA.1, eight BA.2	Recurrent in immunocompromised patients
ORF8	I121L	1	BA.1	Recurrent in immunocompromised patients

742 743

# Figure 2: Distribution of single nucleotide polymorphisms and non-synonymous vs. 744

745 synonymous mutations detected during persistent infections. (a) Frequency of

746 mutations that resulted in a SNP change during one or more persistent infections. (b)

747 Number of synonymous (blue) and non-synonymous (orange) mutations per gene during

748 persistent infections. Numbers on each column show the total counts of SNPs in each

749 category of mutations. (c) Description of recurrent mutations and deletions identified during

750 persistent infections. See **Supplementary Table 1** for information about other mutations.

\*\*None of the recurrent mutations were from households with other infections. 751

752  $\Delta$  represents a deletion



Days since first sequence, t

753

754

#### Figure 3: Comparison of viral load dynamics and number of reported symptoms 755

756 during persistent infections and reinfections. Viral load trajectories of persistent 757 infections with (a) relapsing and (b) chronic persistent infections and (c) reinfections with at 758 least three PCR tests taken over the course of infection/until reinfection. (d) Change in cycle 759 threshold (Ct) value and (e) total number of symptoms reported between the first and last 760 time points with sequenced samples for all 381 persistent infections (purple) and 60 761 reinfections (cyan). Viral load at the last time point is significantly lower for persistent 762 infections with Ct value being more than +6.7 (IQR: +3.2,+10.2) units higher at the last time point (paired t-test  $p < 10^{-8}$ ). The difference is less pronounced for reinfections with +2.5 763 (IQR: -1.1, +7.4) units difference between primary infection and reinfections (paired t-test 764 765 p=0.0003). Similarly, persistently infected individuals tend to report fewer number of 766 symptoms at the later stages of their infection compared to reinfections in the last 7 days at 767 the last time point (at which a sequence was obtained) when compared to the first. On 768 average, persistently infected individuals report two more symptoms at the time of their first 769 sequenceable sample (virus samples with a positive Ct<30) relative to their last sample, with a median of 1 (IQR: 0, 4) fewer reported symptoms (paired Wilcoxon  $p < 10^{-29}$ ), while 770 771 reinfected individuals report only one more symptom at the point of primary infection relative 772 to reinfection, with a median of 0 (IQR: 0, 3) fewer reported symptoms (paired Wilcoxon 773 p=0.005).

# 774 **Supplementary figures**





776

Threshold value for calling a shared rare SNP

777 Supplementary Figure 1: Number of persistent infections identified with a shared rare SNP as a function of the threshold for calling a rare SNP. Threshold value of 1 for rare 778 779 SNPs implies the rare SNP is only found in one sequence of that lineage in the ONS-CIS 780 dataset, excluding sequences from any persistently infected individuals. As the threshold 781 value for calling a rare SNP increases, the number of persistent infections (of any duration) 782 identified (black) increases until at some point the threshold value becomes so high that any 783 individual with two or more sequences of the same major lineage would be identified as a 784 persistent infection based on the rare SNP criterion at which point the false positivity rate 785 (magenta) reaches 100%. At threshold value 400 (vertical dashed line) chosen in this study for identifying persistent infections, the percentage of false positives are 0% for BA.1 and 786 787 BA.2 and 3% for Alpha and Delta.









793	Supplementary Figure 2: Phylogenetic relationship between samples from persistent
794	infections and a representative background population per major lineage. Dashed lines
795	connect every pair of sequences from the same individual. All sequences from the same
796	individual are given the same colour. Pairs of sequences for (a) Alpha, (b) Delta, (c)
797	Omicron BA.1, and (d) Omicron BA.2 that belong to persistent infections cluster closely
798	together while reinfections do not. However, some of the sequences in 2 (out of 97)
799	persistent infections with BA.1 and 5 (out of 167) persistent infections with BA.2 have poor
800	bootstrap support (<80) and do not cluster together or cluster in a basal sister relationship. In
801	all of these 7 cases, at least one of the sequences from each individual has a Ct value close
802	to 30 with poor coverage. On the other hand, all sequences that belong to the same
803	individual and have strong bootstrap support (>80) cluster together.





806 Supplementary Figure 3: Days between all pairs of sequences from the same

807 individual with two or more sequences. Pairs of sequences are classified as (i) pairs with

at least one unidentified Pango lineage (green), (ii) pairs with identical major lineage 808 809

(orange), and (iii) pairs from different major lineages. Bottom panel shows the counts of pairs

810 in each of these three categories for the first 200-day time span (highlighted in a dashed

811 rectangle in the top panel). Pairs include all possible combinations of sequences from the

812 same individual. The number of pairs peaks at the 7-, 30-, and 60-day periods due to the

813 sampling frequency of ONS-CIS (see Methods). Note that pairs with identical major lineage

814 may not necessarily have identical Pango lineages (see Methods).







# 829

830 Supplementary Figure 5: Number of single nucleotide polymorphisms detected in 831 pairs of sequences from persistent infections vs. random pairs from a representative 832 background population. Number of Single Nucleotide Variants (SNVs) per site between all 833 the sequences collected from persistent infections (purple) and random pairs from 834 individuals with only a single sequence within the ONS-CIS (blue) as a function of the 835 number of days between each pair. For each major lineage, a pool of sequences from 836 individuals with only one sequence within the ONS-CIS was sub-sampled and 500 random 837 pairs generated for every 20 additional days between samples. For some major lineages 838 where there were fewer than 500 pairs available beyond a certain time point, all possible 839 random pairs within that 20-day period are used. Solid line and shaded area show the 840 median and interquartile range, respectively, for random pairs over time. Note that the line 841 and shaded area in each graph does not represent the rate of evolution but can be deemed 842 as a measure of lineage diversity as a function of time difference between samples. 843





#### 846 Supplementary Figure 6: Pairwise differences between sequences from individuals

847 with two or more sequences. (Left column) Number of single nucleotide polymorphisms 848 (SNPs) between pairs of sequences from each individual with two or more sequences. Pairs 849 include all possible combinations of sequences from the same individual. Vertical dashed 850 line shows the lowest number of SNPs per base for pairs with different major lineages. Any 851 pair with at least one unidentified lineage with a SNP per base smaller than the dashed line 852 is selected as a candidate pair from a persistent infection. Pairs with different major lineages 853 are coloured based on their number of SNPs per base into three groups: (i) pairs with one 854 BA.1 and one BA.2 or BA.4 or BA.5 sequence (orange); (ii) pairs with one BA.2 and one 855 BA.4 or BA.5 sequence (blue); and (iii) pairs with one Omicron (including all BA.x lineages) 856 and one Delta (B.1.617.2), Alpha (B.1.1.7), or B.1.177 sequence (green). (Right column) Proportion of sequences with different number overlapping base pairs. Those with at least 857 858 one unidentified lineage have a lower number of overlapping base pairs relative to pairs with 859 identifiable lineage (i.e. pairs with identical or different major lineage) mainly due to having 860 lower coverage.

# The COVID-19 Genomics UK (COG-UK) consortium 862

- 863 June 2021 V.1 864 865 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 866 Samples and logistics, Sequencing and analysis, Software and analysis tools, and 867 Visualisation: 868 Dr Samuel C Robson PhD<sup>13, 84</sup> 869 870 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 871 Samples and logistics, Sequencing and analysis, and Software and analysis tools: Dr Thomas R Connor PhD <sup>11, 74</sup> and Prof Nicholas J Loman PhD <sup>43</sup> 872 873 874 Leadership and supervision, Metadata curation, Project administration, Samples and 875 logistics, Sequencing and analysis, Software and analysis tools, and Visualisation: 876 Dr Tanya Golubchik PhD <sup>5</sup> 877 878 Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, 879 Sequencing and analysis, and Visualisation: 880 Dr Rocio T Martinez Nunez PhD<sup>46</sup> 881 882 Funding acquisition, Leadership and supervision, Project administration, Samples and 883 logistics, Sequencing and analysis, and Software and analysis tools: Dr David Bonsall PhD <sup>5</sup> 884 885 886 Funding acquisition, Leadership and supervision, Project administration, Sequencing and 887 analysis, Software and analysis tools, and Visualisation: Prof Andrew Rambaut DPhil<sup>104</sup> 888 889 890 Funding acquisition, Metadata curation, Project administration, Samples and logistics, 891 Sequencing and analysis, and Software and analysis tools: 892 Dr Luke B Snell MSc, MBBS<sup>12</sup> 893 894 Leadership and supervision, Metadata curation, Project administration, Samples and 895 logistics, Software and analysis tools, and Visualisation: Rich Livett MSc <sup>116</sup> 896 897 898 Funding acquisition, Leadership and supervision, Metadata curation, Project administration, 899 and Samples and logistics: 900 Dr Catherine Ludden PhD<sup>20,70</sup> 901 902 Funding acquisition, Leadership and supervision, Metadata curation, Samples and logistics, 903 and Sequencing and analysis: Dr Sally Corden PhD <sup>74</sup> and Dr Eleni Nastouli FRCPath <sup>96, 95, 30</sup> 904 905 906 Funding acquisition, Leadership and supervision, Metadata curation, Sequencing and analysis, and Software and analysis tools: 907
- Dr Gaia Nebbia PhD, FRCPath<sup>12</sup> 908

909	
910 911	Funding acquisition, Leadership and supervision, Project administration, Samples and logistics, and Sequencing and analysis:
912	Ian Johnston BSc <sup>116</sup>
913 914 015	Leadership and supervision, Metadata curation, Project administration, Samples and
916 917	Prof Katrina Lythgoe PhD <sup>5</sup> , Dr M. Estee Torok FRCP <sup>19, 20</sup> and Prof Ian G Goodfellow PhD <sup>24</sup> Leadership and supervision, Metadata curation, Project administration, Samples and
918	logistics, and Visualisation:
919 920	Dr Jacqui A Prieto PhD <sup>97, 82</sup> and Dr Kordo Saeed MD, FRCPath <sup>97, 83</sup>
921 922 923	Leadership and supervision, Metadata curation, Project administration, Sequencing and analysis, and Software and analysis tools: Dr David K Jackson PhD <sup>116</sup>
924 925 926	Leadership and supervision, Metadata curation, Samples and logistics, Sequencing and analysis, and Visualisation:
927	Dr Catherine Houlihan PhD 90, 94
928 929	Leadership and supervision. Metadata curation. Sequencing and analysis. Software and
930	analysis tools, and Visualisation:
931 932	Dr Dan Frampton PhD <sup>94, 95</sup>
933 934	Metadata curation, Project administration, Samples and logistics, Sequencing and analysis, and Software and analysis tools:
935 936	Dr William L Hamilton PhD <sup>19</sup> and Dr Adam A Witney PhD <sup>41</sup>
937 938 939	Funding acquisition, Samples and logistics, Sequencing and analysis, and Visualisation: Dr Giselda Bucca PhD <sup>101</sup>
940 941	Funding acquisition, Leadership and supervision, Metadata curation, and Project administration:
942	Dr Cassie F Pope PhD <sup>40, 41</sup>
943	
944	Funding acquisition, Leadership and supervision, Metadata curation, and Samples and
945 046	logistics:
940 947	
948	Funding acquisition, Leadership and supervision, Metadata curation, and Sequencing and
949	analysis:
950	Prof Emma C Thomson PhD, FRCP 53
951	
952	Funding acquisition, Leadership and supervision, Project administration, and Samples and
953	
954 055	Dr Ewan M Harrison PhD 110, 102
955 956	Funding acquisition, Leadership and supervision, Sequencing and analysis, and

957	Visualisation:
958	Prof Colin P Smith PhD <sup>101</sup>
959	
960	Leadership and supervision Metadata curation Project administration and Sequencing and
961	analysis:
062	Fiona Rogan BSc <sup>77</sup>
062	Tiona Rogan Doc
903	Landership and supervision. Metadata suration. Project administration, and Samples and
904	
900	IOGISIICS: Chave M. Daalevitte M.Ca <sup>6</sup> , Aleinail Murray, Daarea <sup>6</sup> , Dave Ciastatas UNC <sup>6</sup> , Da Kinstiaa
900	Snaun M Beckwith MSC °, Abigail Murray Degree °, Dawn Singleton HNC °, Dr Kirstine
967	Eastick PhD, FRCPath <sup>or</sup> , Dr Liz A Sheridan PhD <sup>oo</sup> , Paul Randell MSc, PgD <sup>oo</sup> , Dr Leigh M
968	Jackson PhD 103, Dr Cristina V Ariani PhD 116 and Dr Sónia Gonçalves PhD 116
969	
970	Leadership and supervision, Metadata curation, Samples and logistics, and Sequencing and
971	analysis:
972	Dr Derek J Fairley PhD <sup>3, 77</sup> , Prof Matthew W Loose PhD <sup>18</sup> and Joanne Watkins MSc <sup>74</sup>
973	
974	
975	Leadership and supervision, Metadata curation, Samples and logistics, and Visualisation:
976	Dr Samuel Moses MD <sup>25, 106</sup>
977	
978	Leadership and supervision. Metadata curation. Sequencing and analysis, and Software and
979	analysis tools.
980	Dr Sam Nicholls PhD $^{43}$ Dr Matthew Bull PhD $^{74}$ and Dr Roberto Amato PhD $^{116}$
081	
901	Leadership and supervision. Project administration. Samples and legistics, and Sequencing
90Z	and analysis
903	Drof Darron L. Smith DhD <sup>36, 65, 66</sup>
904 005	
965	Leadership and survey ising. On ware in a surd as sharing Orffusion and survey is table and
986	Leadership and supervision, Sequencing and analysis, Software and analysis tools, and
987	
988	Prof David M Aanensen PhD 14, 118 and Dr Jeffrey C Barrett PhD 118
989	
990	Metadata curation, Project administration, Samples and logistics, and Sequencing and
991	analysis:
992	Dr Dinesh Aggarwal MRCP <sup>20, 116, 70</sup> , Dr James G Shepherd MBCHB, MRCP <sup>53</sup> , Dr Martin D
993	Curran PhD <sup>71</sup> and Dr Surendra Parmar PhD <sup>71</sup>
994	
995	Metadata curation, Project administration, Sequencing and analysis, and Software and
996	analysis tools:
997	Dr Matthew D Parker PhD <sup>109</sup>
998	
999	Metadata curation. Samples and logistics. Sequencing and analysis, and Software and
1000	analysis tools:
1001	Dr Catryn Williams PhD <sup>74</sup>
1007	
1002	Metadata curation. Samples and logistics. Sequencing and analysis, and Visualisation:
1003	nierauara curation, camples and logistics, cequenting and analysis, and visualisation.
1004	DI SHAIDH GIAYSHEL FHD

1005	
1006	Metadata curation, Sequencing and analysis, Software and analysis tools, and Visualisation:
1007	Dr Anthony P Underwood PhD <sup>14, 116</sup> , Dr Matthew Bashton PhD <sup>36, 65</sup> , Dr Nicole Pacchiarini
1008	PhD <sup>74</sup> , Dr Katie F Loveson PhD <sup>84</sup> and Matthew Byott MSc <sup>95, 96</sup>
1009	
1010	Project administration, Sequencing and analysis, Software and analysis tools, and
1011	Visualisation:
1012	Dr Alessandro M Carabelli PhD 20
1013	
1014	Funding acquisition, Leadership and supervision, and Metadata curation:
1015	Dr Kate E Templeton PhD <sup>56, 104</sup>
1016	
1017	Funding acquisition, Leadership and supervision, and Project administration:
1018	Dr Thushan I de Silva PhD <sup>109</sup> , Dr Dennis Wang PhD <sup>109</sup> , Dr Cordelia F Langford PhD <sup>116</sup> and
1019	John Sillitoe BEng <sup>116</sup>
1020	
1021	Funding acquisition, Leadership and supervision, and Samples and logistics:
1022	Prof Rory N Gunson PhD, FRCPath <sup>55</sup>
1023	
1024	Funding acquisition, Leadership and supervision, and Sequencing and analysis:
1025	Dr Simon Cottrell PhD <sup>74</sup> , Dr Justin O'Grady PhD <sup>75, 103</sup> and Prof Dominic Kwiatkowski PhD
1026	116, 108
1027	
1028	Leadership and supervision, Metadata curation, and Project administration:
1029	Dr Patrick J Lillie PhD, FRCP 37
1030	
1031	Leadership and supervision, Metadata curation, and Samples and logistics:
1032	Dr Nicholas Cortes MBCHB <sup>33</sup> , Dr Nathan Moore MBCHB <sup>33</sup> , Dr Claire Thomas DPhil <sup>33</sup> ,
1033	Phillipa J Burns MSc, DipRCPath <sup>37</sup> , Dr Tabitha W Mahungu FRCPath <sup>80</sup> and Steven Liggett
1034	BSc <sup>86</sup>
1035	
1036	Leadership and supervision, Metadata curation, and Sequencing and analysis:
1037	Angela H Beckett MSc <sup>13, 31</sup> and Prof Matthew TG Holden PhD <sup>73</sup>
1038	
1039	Leadership and supervision, Project administration, and Samples and logistics:
1040	Dr Lisa J Levett PhD <sup>34</sup> , Dr Husam Osman PhD <sup>70, 35</sup> and Dr Mohammed O Hassan-Ibrahim
1041	PhD, FRCPath <sup>38</sup>
1042	
1043	Leadership and supervision, Project administration, and Sequencing and analysis:
1044	Dr David A Simpson PhD "
1045	Leadership and supervision. Operates and braiting and Operating and enclosing
1046	Leadership and supervision, Samples and logistics, and Sequencing and analysis:
1047	Dr ivieera Chang PhD <sup></sup> , Prot Ravi K Gupta PhD <sup></sup> , Prot Alistair C Darby PhD <sup></sup> and Prot
1040 1040	
1049	Loadership and europyinian. Sequencing and englypic, and Seffyers and englypic tables
1050	Leavership and supervision, bequencing and analysis, and Soltware and analysis tools: Prof Olivor C Dubus DDbil <sup>23</sup> Dr Erik M Volz DbD <sup>39</sup> Drof Dobiolo do Apapilio DbD <sup>52</sup> Drof
1001	Proto Univer G Fybus DFIII, DI ETIK IVI VOIZ FIID, FIOI DATIETA de Angelis FIID <sup>52</sup> , Prot
1002	David L Robertson Fild , Di Andrew J Fage Fild and Dr Inigo Martincorena PND

1053	
1054	Leadership and supervision. Sequencing and analysis, and Visualisation:
1055	Dr Louise Aigrain PhD <sup>116</sup> and Dr Andrew R Bassett PhD <sup>116</sup>
1056	
1057	Metadata curation Project administration and Samples and logistics:
1058	Dr Nick Wong DPhil MRCP FRCPath <sup>50</sup> Dr Yusri Taha MD PhD <sup>89</sup> Michelle J Erkiert BA <sup>99</sup>
1059	and Dr Michael H Spencer Chapman MBBS <sup>116, 102</sup>
1060	
1061	Metadata curation Project administration and Sequencing and analysis:
1062	Dr Rebecca Dewar PhD <sup>56</sup> and Martin P McHugh MSc <sup>56, 111</sup>
1063	
1064	Metadata curation Project administration and Software and analysis tools:
1065	Siddharth Mookeriee MPH <sup>38, 57</sup>
1066	
1067	Metadata curation Project administration and Visualisation
1068	Stephen Aplin <sup>97</sup> Matthew Harvey <sup>97</sup> Thea Sass <sup>97</sup> Dr Helen Umpleby ERCP <sup>97</sup> and Helen
1069	Wheeler <sup>97</sup>
1070	
1071	Metadata curation, Samples and logistics, and Sequencing and analysis:
1072	Dr James P McKenna PhD <sup>3</sup> . Dr Ben Warne MRCP <sup>9</sup> . Joshua F Taylor MSc <sup>22</sup> . Yasmin
1073	Chaudhry BSc <sup>24</sup> . Rhys Izuagbe <sup>24</sup> . Dr Aminu S Jahun PhD <sup>24</sup> . Dr Gregory R Young PhD <sup>36</sup> ,
1074	<sup>65</sup> . Dr Claire McMurray PhD <sup>43</sup> . Dr Clare M McCann PhD <sup>65, 66</sup> . Dr Andrew Nelson PhD <sup>65, 66</sup>
1075	and Scott Elliott <sup>68</sup>
1076	
1077	Metadata curation, Samples and logistics, and Visualisation:
1078	Hannah Lowe MSc <sup>25</sup>
1079	
1080	Metadata curation, Sequencing and analysis, and Software and analysis tools:
1081	Dr Anna Price PhD <sup>11</sup> , Matthew R Crown BSc <sup>65</sup> , Dr Sara Rey PhD <sup>74</sup> , Dr Sunando Roy PhD
1082	<sup>96</sup> and Dr Ben Temperton PhD <sup>105</sup>
1083	
1084	
1085	Metadata curation, Sequencing and analysis, and Visualisation:
1086	Dr Sharif Shaaban PhD <sup>73</sup> and Dr Andrew R Hesketh PhD <sup>101</sup>
1087	
1088	Project administration, Samples and logistics, and Sequencing and analysis:
1089	Dr Kenneth G Laing PhD <sup>41</sup> , Dr Irene M Monahan PhD <sup>41</sup> and Dr Judith Heaney PhD <sup>95,96,34</sup>
1090	
1091	Project administration, Samples and logistics, and Visualisation:
1092	Dr Emanuela Pelosi FRCPath <sup>97</sup> , Siona Silviera MSc <sup>97</sup> and Dr Eleri Wilson-Davies MD,
1093	FRCPath <sup>97</sup>
1094	
1095	Samples and logistics, Software and analysis tools, and Visualisation:
1096	Dr Helen Fryer PhD <sup>5</sup>
1097	
1098	Sequencing and analysis, Software and analysis tools, and Visualization:
1099	Dr Helen Adams PhD $^4$ , Dr Louis du Plessis PhD $^{23}$ , Dr Rob Johnson PhD $^{39}$ , Dr William T
1100	Harvey PhD <sup>53, 42</sup> , Dr Joseph Hughes PhD <sup>53</sup> , Dr Richard J Orton PhD <sup>53</sup> , Dr Lewis G Spurgin

PhD <sup>59</sup>, Dr Yann Bourgeois PhD <sup>81</sup>, Dr Chris Ruis PhD <sup>102</sup>, Áine O'Toole MSc <sup>104</sup>, Marina 1101 Gourtovaia MSc <sup>116</sup> and Dr Theo Sanderson PhD <sup>116</sup> 1102 1103 1104 Funding acquisition, and Leadership and supervision: Dr Christophe Fraser PhD<sup>5</sup>, Dr Jonathan Edgeworth PhD, FRCPath<sup>12</sup>, Prof Judith Breuer 1105 MD <sup>96, 29</sup>, Dr Stephen L Michell PhD <sup>105</sup> and Prof John A Todd PhD <sup>115</sup> 1106 1107 1108 Funding acquisition, and Project administration: Michaela John BSc <sup>10</sup> and Dr David Buck PhD <sup>115</sup> 1109 1110 1111 Leadership and supervision, and Metadata curation: Dr Kavitha Gajee MBBS, FRCPath <sup>37</sup> and Dr Gemma L Kay PhD <sup>75</sup> 1112 1113 1114 Leadership and supervision, and Project administration: 1115 Prof Sharon J Peacock PhD <sup>20, 70</sup> and David Heyburn <sup>74</sup> 1116 1117 Leadership and supervision, and Samples and logistics: Katie Kitchman BSc <sup>37</sup>, Prof Alan McNally PhD <sup>43, 93</sup>, David T Pritchard MSc, CSci <sup>50</sup>, Dr 1118 Samir Dervisevic FRCPath <sup>58</sup>, Dr Peter Muir PhD <sup>70</sup>, Dr Esther Robinson PhD <sup>70, 35</sup>, Dr Barry 1119 B Vipond PhD <sup>70</sup>, Newara A Ramadan MSc, CSci, FIBMS <sup>78</sup>, Dr Christopher Jeanes MBBS 1120 <sup>90</sup>, Danni Weldon BSc <sup>116</sup>, Jana Catalan MSc <sup>118</sup> and Neil Jones MSc <sup>118</sup> 1121 1122 Leadership and supervision, and Sequencing and analysis: 1123 Dr Ana da Silva Filipe PhD <sup>53</sup>, Dr Chris Williams MBBS <sup>74</sup>, Marc Fuchs BSc <sup>77</sup>, Dr Julia 1124 Miskelly PhD <sup>77</sup>, Dr Aaron R Jeffries PhD <sup>105</sup>, Karen Oliver BSc <sup>116</sup> and Dr Naomi R Park PhD 1125 116 1126 1127 Metadata curation, and Samples and logistics: 1128 Amy Ash BSc<sup>1</sup>, Cherian Koshy MSc, CSci, FIBMS<sup>1</sup>, Magdalena Barrow<sup>7</sup>, Dr Sarah L 1129 Buchan PhD<sup>7</sup>, Dr Anna Mantzouratou PhD<sup>7</sup>, Dr Gemma Clark PhD<sup>15</sup>, Dr Christopher W 1130 1131 Holmes PhD <sup>16</sup>, Sharon Campbell MSc <sup>17</sup>, Thomas Davis MSc <sup>21</sup>, Ngee Keong Tan MSc <sup>22</sup>, Dr Julianne R Brown PhD<sup>29</sup>, Dr Kathryn A Harris PhD<sup>29, 2</sup>, Stephen P Kidd MSc<sup>33</sup>, Dr Paul 1132 Li Xu-McCrae PhD <sup>35</sup>, Dr Alison Cox PhD <sup>38, 63</sup>, Pinglawathee Madona R Grant PhD <sup>34</sup>. Dr 1133 <sup>38, 63</sup>, Dr Marcus Pond PhD <sup>38, 63</sup>, Dr Paul A Randell MBBCh <sup>38, 63</sup>, Karen T Withell FIBMS <sup>48</sup>, 1134 Cheryl Williams MSc <sup>51</sup>, Dr Clive Graham MD <sup>60</sup>, Rebecca Denton-Smith BSc <sup>62</sup>, Emma 1135 Swindells BSc <sup>62</sup>, Robyn Turnbull BSc <sup>62</sup>, Dr Tim J Sloan PhD <sup>67</sup>, Dr Andrew Bosworth PhD 1136 <sup>70, 35</sup>, Stephanie Hutchings <sup>70</sup>, Hannah M Pymont MSc <sup>70</sup>, Dr Anna Casey PhD <sup>76</sup>, Dr Liz 1137 Ratcliffe PhD <sup>76</sup>, Dr Christopher R Jones PhD <sup>79, 105</sup>, Dr Bridget A Knight PhD <sup>79, 105</sup>, Dr 1138 Tanzina Haque PhD, FRCPath<sup>80</sup>, Dr Jennifer Hart MRCP<sup>80</sup>, Dr Dianne Irish-Tavares 1139 FRCPath <sup>80</sup>, Eric Witele MSc <sup>80</sup>, Craig Mower BA <sup>86</sup>, Louisa K Watson DipHE <sup>86</sup>, Jennifer 1140 Collins BSc <sup>89</sup>, Gary Eltringham BSc <sup>89</sup>, Dorian Crudgington <sup>98</sup>, Ben Macklin <sup>98</sup>, Prof Miren 1141 Iturriza-Gomara PhD<sup>107</sup>, Dr Anita O Lucaci PhD<sup>107</sup> and Dr Patrick C McClure PhD<sup>113</sup> 1142 1143 Metadata curation, and Sequencing and analysis: 1144 Matthew Carlile BSc <sup>18</sup>, Dr Nadine Holmes PhD <sup>18</sup>, Dr Christopher Moore PhD <sup>18</sup>, Dr 1145 Nathaniel Storey PhD<sup>29</sup>, Dr Stefan Rooke PhD<sup>73</sup>, Dr Gonzalo Yebra PhD<sup>73</sup>, Dr Noel Craine 1146 DPhil<sup>74</sup>, Malorie Perry MSc<sup>74</sup>, Dr Nabil-Fareed Alikhan PhD<sup>75</sup>, Dr Stephen Bridgett PhD<sup>77</sup>, 1147 Kate F Cook MScR<sup>84</sup>, Christopher Fearn MSc<sup>84</sup>, Dr Salman Goudarzi PhD<sup>84</sup>, Prof Ronan A 1148

Lyons MD <sup>88</sup>, Dr Thomas Williams MD <sup>104</sup>, Dr Sam T Haldenby PhD <sup>107</sup>, Jillian Durham BSc 1149 <sup>116</sup> and Dr Steven Leonard PhD <sup>116</sup> 1150 1151 Metadata curation, and Software and analysis tools: 1152 Robert M Davies MA (Cantab) <sup>116</sup> 1153 1154 1155 Project administration, and Samples and logistics: Dr Rahul Batra MD<sup>12</sup>, Beth Blane BSc<sup>20</sup>, Dr Moira J Spyer PhD<sup>30, 95, 96</sup>, Perminder Smith 1156 MSc <sup>32, 112</sup>, Mehmet Yavus <sup>85, 109</sup>, Dr Rachel J Williams PhD <sup>96</sup>, Dr Adhyana IK Mahanama 1157 MD <sup>97</sup>, Dr Buddhini Samaraweera MD <sup>97</sup>, Sophia T Girgis MSc <sup>102</sup>, Samantha E Hansford 1158 CSci <sup>109</sup>, Dr Angie Green PhD <sup>115</sup>, Dr Charlotte Beaver PhD <sup>116</sup>, Katherine L Bellis <sup>116, 102</sup>, 1159 Matthew J Dorman<sup>116</sup>, Sally Kay<sup>116</sup>, Liam Prestwood<sup>116</sup> and Dr Shavanthi Rajatileka PhD 1160 116 1161 1162 1163 Project administration, and Sequencing and analysis: 1164 Dr Joshua Quick PhD 43 1165 1166 Project administration, and Software and analysis tools: Radoslaw Poplawski BSc <sup>43</sup> 1167 1168 1169 Samples and logistics, and Sequencing and analysis: Dr Nicola Reynolds PhD<sup>8</sup>, Andrew Mack MPhil<sup>11</sup>, Dr Arthur Morriss PhD<sup>11</sup>, Thomas 1170 Whalley BSc <sup>11</sup>, Bindi Patel BSc <sup>12</sup>, Dr Iliana Georgana PhD <sup>24</sup>, Dr Myra Hosmillo PhD <sup>24</sup>, 1171 Malte L Pinckert MPhil <sup>24</sup>, Dr Joanne Stockton PhD <sup>43</sup>, Dr John H Henderson PhD <sup>65</sup>, Amy 1172 Hollis HND <sup>65</sup>, Dr William Stanley PhD <sup>65</sup>, Dr Wen C Yew PhD <sup>65</sup>, Dr Richard Myers PhD <sup>72</sup>, 1173 Dr Alicia Thornton PhD <sup>72</sup>, Alexander Adams BSc <sup>74</sup>, Tara Annett BSc <sup>74</sup>, Dr Hibo Asad PhD 1174 <sup>74</sup>, Alec Birchley MSc <sup>74</sup>, Jason Coombes BSc <sup>74</sup>, Johnathan M Evans MSc <sup>74</sup>, Laia Fina <sup>74</sup>, 1175 Bree Gatica-Wilcox MPhil <sup>74</sup>, Lauren Gilbert <sup>74</sup>, Lee Graham BSc <sup>74</sup>, Jessica Hey BSc <sup>74</sup>, 1176 Ember Hilvers MPH <sup>74</sup>, Sophie Jones MSc <sup>74</sup>, Hannah Jones <sup>74</sup>, Sara Kumziene-1177 Summerhayes MSc <sup>74</sup>, Dr Caoimhe McKerr PhD <sup>74</sup>, Jessica Powell BSc <sup>74</sup>, Georgia Pugh <sup>74</sup>, 1178 1179 Sarah Taylor <sup>74</sup>, Alexander J Trotter MRes <sup>75</sup>, Charlotte A Williams BSc <sup>96</sup>, Leanne M Kermack MSc <sup>102</sup>, Benjamin H Foulkes MSc <sup>109</sup>, Marta Gallis MSc <sup>109</sup>, Hailey R Hornsby MSc 1180 <sup>109</sup>, Stavroula F Louka MSc <sup>109</sup>, Dr Manoj Pohare PhD <sup>109</sup>, Paige Wolverson MSc <sup>109</sup>, Peijun 1181 Zhang MSc <sup>109</sup>, George MacIntyre-Cockett BSc <sup>115</sup>, Amy Trebes MSc <sup>115</sup>, Dr Robin J Moll 1182 PhD <sup>116</sup>, Lynne Ferguson MSc <sup>117</sup>, Dr Emily J Goldstein PhD <sup>117</sup>, Dr Alasdair Maclean PhD <sup>117</sup> 1183 and Dr Rachael Tomb PhD <sup>117</sup> 1184 1185 1186 Samples and logistics, and Software and analysis tools: Dr Igor Starinskij MSc. MRCP 53 1187 1188 1189 Sequencing and analysis, and Software and analysis tools: Laura Thomson BSc <sup>5</sup>, Joel Southgate MSc <sup>11, 74</sup>, Dr Moritz UG Kraemer DPhil <sup>23</sup>, Dr Jayna 1190 Raghwani PhD<sup>23</sup>, Dr Alex E Zarebski PhD<sup>23</sup>, Olivia Boyd MSc<sup>39</sup>, Lily Geidelberg MSc<sup>39</sup>, Dr 1191 Chris J Illingworth PhD <sup>52</sup>, Dr Chris Jackson PhD <sup>52</sup>, Dr David Pascall PhD <sup>52</sup>, Dr Sreenu 1192 Vattipally PhD <sup>53</sup>, Timothy M Freeman MPhil <sup>109</sup>, Dr Sharon N Hsu PhD <sup>109</sup>, Dr Benjamin B 1193 Lindsey MRCP <sup>109</sup>, Dr Keith James PhD <sup>116</sup>, Kevin Lewis <sup>116</sup>, Gerry Tonkin-Hill <sup>116</sup> and Dr 1194 Jaime M Tovar-Corona PhD <sup>116</sup> 1195 1196

#### 1197 Sequencing and analysis, and Visualisation:

- MacGregor Cox MSci 20 1198
- 1199
- 1200 Software and analysis tools, and Visualisation:
- Dr Khalil Abudahab PhD<sup>14, 116</sup>, Mirko Menegazzo<sup>14</sup>, Ben EW Taylor MEng<sup>14, 116</sup>, Dr Corin A 1201 Yeats PhD<sup>14</sup>, Afrida Mukaddas BTech<sup>53</sup>, Derek W Wright MSc<sup>53</sup>, Dr Leonardo de Oliveira 1202 Martins PhD<sup>75</sup>, Dr Rachel Colquhoun DPhil<sup>104</sup>, Verity Hill<sup>104</sup>, Dr Ben Jackson PhD<sup>104</sup>, Dr JT 1203
- McCrone PhD <sup>104</sup>, Dr Nathan Medd PhD <sup>104</sup>, Dr Emily Scher PhD <sup>104</sup> and Jon-Paul Keatley <sup>116</sup> 1204
- 1205
- 1206 Leadership and supervision:
- 1207 Dr Tanya Curran PhD<sup>3</sup>, Dr Sian Morgan FRCPath<sup>10</sup>, Prof Patrick Maxwell PhD<sup>20</sup>, Prof Ken Smith PhD<sup>20</sup>, Dr Sahar Eldirdiri MBBS, MSc, FRCPath<sup>21</sup>, Anita Kenyon MSc<sup>21</sup>, Prof Alison 1208 H Holmes MD <sup>38, 57</sup>, Dr James R Price PhD <sup>38, 57</sup>, Dr Tim Wyatt PhD <sup>69</sup>, Dr Alison E Mather 1209 PhD <sup>75</sup>, Dr Timofey Skvortsov PhD <sup>77</sup> and Prof John A Hartley PhD <sup>96</sup> 1210
- 1211
- 1212 Metadata curation:
- Prof Martyn Guest PhD<sup>11</sup>, Dr Christine Kitchen PhD<sup>11</sup>, Dr Ian Merrick PhD<sup>11</sup>, Robert Munn 1213 BSc<sup>11</sup>, Dr Beatrice Bertolusso Degree <sup>33</sup>, Dr Jessica Lynch MBCHB <sup>33</sup>, Dr Gabrielle Vernet 1214 MBBS <sup>33</sup>, Stuart Kirk MSc <sup>34</sup>, Dr Elizabeth Wastnedge MD <sup>56</sup>, Dr Rachael Stanley PhD <sup>58</sup>, 1215 Giles Idle <sup>64</sup>, Dr Declan T Bradley PhD <sup>69, 77</sup>, Dr Jennifer Poyner MD <sup>79</sup> and Matilde Mori BSc 1216 110
- 1217
- 1218
- 1219 Project administration:
- Owen Jones BSc <sup>11</sup>, Victoria Wright BSc <sup>18</sup>, Ellena Brooks MA <sup>20</sup>, Carol M Churcher BSc <sup>20</sup>, 1220 Mireille Fragakis HND <sup>20</sup>, Dr Katerina Galai PhD <sup>20, 70</sup>, Dr Andrew Jermy PhD <sup>20</sup>, Sarah 1221 Judges BA <sup>20</sup>, Georgina M McManus BSc <sup>20</sup>, Kim S Smith <sup>20</sup>, Dr Elaine Westwick PhD <sup>20</sup>, Dr 1222 Stephen W Attwood PhD<sup>23</sup>, Dr Frances Bolt PhD<sup>38, 57</sup>, Dr Alisha Davies PhD<sup>74</sup>, Elen De 1223 Lacy MPH <sup>74</sup>, Fatima Downing <sup>74</sup>, Sue Edwards <sup>74</sup>, Lizzie Meadows MA <sup>75</sup>, Sarah Jeremiah 1224 MSc <sup>97</sup>, Dr Nikki Smith PhD <sup>109</sup> and Luke Foulser <sup>116</sup> 1225
- 1226
- 1227 Samples and logistics:
- Dr Themoula Charalampous PhD<sup>12, 46</sup>, Amita Patel BSc<sup>12</sup>, Dr Louise Berry PhD<sup>15</sup>, Dr Tim 1228 Boswell PhD<sup>15</sup>, Dr Vicki M Fleming PhD<sup>15</sup>, Dr Hannah C Howson-Wells PhD<sup>15</sup>, Dr Amelia 1229 Joseph PhD<sup>15</sup>, Manjinder Khakh<sup>15</sup>, Dr Michelle M Lister PhD<sup>15</sup>, Paul W Bird MSc, MRes<sup>16</sup>, 1230 Karlie Fallon<sup>16</sup>, Thomas Helmer<sup>16</sup>, Dr Claire L McMurray PhD<sup>16</sup>, Mina Odedra BSc<sup>16</sup>, 1231 Jessica Shaw BSc <sup>16</sup>, Dr Julian W Tang PhD <sup>16</sup>, Nicholas J Willford MSc <sup>16</sup>, Victoria Blakey 1232 BSc <sup>17</sup>, Dr Veena Raviprakash MD <sup>17</sup>, Nicola Sheriff BSc <sup>17</sup>, Lesley-Anne Williams BSc <sup>17</sup>, 1233 Theresa Feltwell MSc <sup>20</sup>, Dr Luke Bedford PhD <sup>26</sup>, Dr James S Cargill PhD <sup>27</sup>, Warwick 1234 Hughes MSc<sup>27</sup>, Dr Jonathan Moore MD<sup>28</sup>, Susanne Stonehouse BSc<sup>28</sup>, Laura Atkinson 1235 MSc <sup>29</sup>, Jack CD Lee MSc <sup>29</sup>, Dr Divya Shah PhD <sup>29</sup>, Adela Alcolea-Medina Clinical scientist 1236 <sup>32, 112</sup>, Natasha Ohemeng-Kumi MSc <sup>32, 112</sup>, John Ramble MSc <sup>32, 112</sup>, Jasveen Sehmi MSc <sup>32,</sup> 1237 <sup>112</sup>, Dr Rebecca Williams BMBS <sup>33</sup>, Wendy Chatterton MSc <sup>34</sup>, Monika Pusok MSc <sup>34</sup>, William 1238 Everson MSc <sup>37</sup>, Anibolina Castigador IBMS HCPC <sup>44</sup>, Emily Macnaughton FRCPath <sup>44</sup>, Dr 1239 Kate El Bouzidi MRCP<sup>45</sup>, Dr Temi Lampejo FRCPath<sup>45</sup>, Dr Malur Sudhanva FRCPath<sup>45</sup>, 1240 Cassie Breen BSc <sup>47</sup>, Dr Graciela Sluga MD, MSc <sup>48</sup>, Dr Shazaad SY Ahmad MSc <sup>49, 70</sup>, Dr 1241 Ryan P George PhD<sup>49</sup>, Dr Nicholas W Machin MSc<sup>49,70</sup>, Debbie Binns BSc<sup>50</sup>, Victoria 1242 James BSc <sup>50</sup>, Dr Rachel Blacow MBCHB <sup>55</sup>, Dr Lindsay Coupland PhD <sup>58</sup>, Dr Louise Smith 1243 PhD <sup>59</sup>, Dr Edward Barton MD <sup>60</sup>, Debra Padgett BSc <sup>60</sup>, Garren Scott BSc <sup>60</sup>, Dr Aidan Cross 1244

MBCHB <sup>61</sup>, Dr Mariyam Mirfenderesky FRCPath <sup>61</sup>, Jane Greenaway MSc <sup>62</sup>, Kevin Cole <sup>64</sup>, 1245 Phillip Clarke <sup>67</sup>, Nichola Duckworth <sup>67</sup>, Sarah Walsh <sup>67</sup>, Kelly Bicknell <sup>68</sup>, Robert Impey MSc 1246 <sup>68</sup>, Dr Sarah Wyllie PhD <sup>68</sup>, Richard Hopes <sup>70</sup>, Dr Chloe Bishop PhD <sup>72</sup>, Dr Vicki Chalker PhD 1247 <sup>72</sup>, Dr Ian Harrison PhD <sup>72</sup>, Laura Gifford MSc <sup>74</sup>, Dr Zoltan Molnar PhD <sup>77</sup>, Dr Cressida 1248 Auckland FRCPath <sup>79</sup>, Dr Cariad Evans PhD <sup>85, 109</sup>, Dr Kate Johnson PhD <sup>85, 109</sup>, Dr David G 1249 Partridge FRCP, FRCPath <sup>85, 109</sup>, Dr Mohammad Raza PhD <sup>85, 109</sup>, Paul Baker MD <sup>86</sup>, Prof 1250 Stephen Bonner PhD <sup>86</sup>, Sarah Essex <sup>86</sup>, Leanne J Murray <sup>86</sup>, Andrew I Lawton MSc <sup>87</sup>, Dr 1251 Shirelle Burton-Fanning MD<sup>89</sup>, Dr Brendan Al Payne MD<sup>89</sup>, Dr Sheila Waugh MD<sup>89</sup>, Andrea 1252 N Gomes MSc <sup>91</sup>, Maimuna Kimuli MSc <sup>91</sup>, Darren R Murray MSc <sup>91</sup>, Paula Ashfield MSc <sup>92</sup>, 1253 Dr Donald Dobie MBCHB <sup>92</sup>, Dr Fiona Ashford PhD <sup>93</sup>, Dr Angus Best PhD <sup>93</sup>, Dr Liam 1254 Crawford PhD <sup>93</sup>, Dr Nicola Cumley PhD <sup>93</sup>, Dr Megan Mayhew PhD <sup>93</sup>, Dr Oliver Megram 1255 PhD <sup>93</sup>, Dr Jeremy Mirza PhD <sup>93</sup>, Dr Emma Moles-Garcia PhD <sup>93</sup>, Dr Benita Percival PhD <sup>93</sup>, 1256 Megan Driscoll BSc <sup>96</sup>, Leah Ensell BSc <sup>96</sup>, Dr Helen L Lowe PhD <sup>96</sup>, Laurentiu Maftei BSc <sup>96</sup>, 1257 Matteo Mondani MSc <sup>96</sup>, Nicola J Chaloner BSc <sup>99</sup>, Benjamin J Cogger BSc <sup>99</sup>, Lisa J Easton 1258 MSc <sup>99</sup>, Hannah Huckson BSc <sup>99</sup>, Jonathan Lewis MSc, PgD, FIBMS <sup>99</sup>, Sarah Lowdon BSc 1259 <sup>99</sup>, Cassandra S Malone MSc <sup>99</sup>, Florence Munemo BSc <sup>99</sup>, Manasa Mutingwende MSc <sup>99</sup>, 1260 Roberto Nicodemi BSc <sup>99</sup>, Olga Podplomyk FD <sup>99</sup>, Thomas Somassa BSc <sup>99</sup>, Dr Andrew 1261 Beggs PhD <sup>100</sup>, Dr Alex Richter PhD <sup>100</sup>, Claire Cormie <sup>102</sup>, Joana Dias MSc <sup>102</sup>, Sally Forrest 1262 BSc <sup>102</sup>, Dr Ellen E Higginson PhD <sup>102</sup>, Mailis Maes MPhil <sup>102</sup>, Jamie Young BSc <sup>102</sup>, Dr Rose 1263 K Davidson PhD <sup>103</sup>, Kathryn A Jackson MSc <sup>107</sup>, Dr Lance Turtle PhD, MRCP <sup>107</sup>, Dr 1264 Alexander J Keeley MRCP<sup>109</sup>, Prof Jonathan Ball PhD<sup>113</sup>, Timothy Byaruhanga MSc<sup>113</sup>, Dr 1265 Joseph G Chappell PhD<sup>113</sup>, Jayasree Dey MSc<sup>113</sup>, Jack D Hill MSc<sup>113</sup>, Emily J Park MSc 1266 <sup>113</sup>, Arezou Fanaie MSc <sup>114</sup>, Rachel A Hilson MSc <sup>114</sup>, Geraldine Yaze MSc <sup>114</sup> and Stephanie 1267 Lo <sup>116</sup> 1268

1269

#### 1270 Sequencing and analysis:

Safiah Afifi BSc <sup>10</sup>, Robert Beer BSc <sup>10</sup>, Joshua Maksimovic FD <sup>10</sup>, Kathryn McCluggage 1271 Masters <sup>10</sup>, Karla Spellman FD <sup>10</sup>, Catherine Bresner BSc <sup>11</sup>, William Fuller BSc <sup>11</sup>, Dr Angela 1272 Marchbank BSc <sup>11</sup>, Trudy Workman HNC <sup>11</sup>, Dr Ekaterina Shelest PhD <sup>13, 81</sup>, Dr Johnny 1273 Debebe PhD <sup>18</sup>, Dr Fei Sang PhD <sup>18</sup>, Dr Marina Escalera Zamudio PhD <sup>23</sup>, Dr Sarah Francois 1274 PhD <sup>23</sup>, Bernardo Gutierrez MSc <sup>23</sup>, Dr Tetyana I Vasylyeva DPhil <sup>23</sup>, Dr Flavia Flaviani PhD 1275 1276 <sup>31</sup>, Dr Manon Ragonnet-Cronin PhD <sup>39</sup>, Dr Katherine L Smollett PhD <sup>42</sup>, Alice Broos BSc <sup>53</sup>, Daniel Mair BSc<sup>53</sup>, Jenna Nichols BSc<sup>53</sup>, Dr Kyriaki Nomikou PhD<sup>53</sup>, Dr Lily Tong PhD<sup>53</sup>, 1277 Ioulia Tsatsani MSc <sup>53</sup>, Prof Sarah O'Brien PhD <sup>54</sup>, Prof Steven Rushton PhD <sup>54</sup>, Dr Roy 1278 Sanderson PhD <sup>54</sup>, Dr Jon Perkins MBCHB <sup>55</sup>, Seb Cotton MSc <sup>56</sup>, Abbie Gallagher BSc <sup>56</sup>, 1279 Dr Elias Allara MD, PhD <sup>70, 102</sup>, Clare Pearson MSc <sup>70, 102</sup>, Dr David Bibby PhD <sup>72</sup>, Dr Gavin 1280 Dabrera PhD<sup>72</sup>, Dr Nicholas Ellaby PhD<sup>72</sup>, Dr Eileen Gallagher PhD<sup>72</sup>, Dr Jonathan Hubb 1281 PhD <sup>72</sup>, Dr Angie Lackenby PhD <sup>72</sup>, Dr David Lee PhD <sup>72</sup>, Nikos Manesis <sup>72</sup>, Dr Tamyo Mbisa 1282 PhD<sup>72</sup>, Dr Steven Platt PhD<sup>72</sup>, Katherine A Twohig<sup>72</sup>, Dr Mari Morgan PhD<sup>74</sup>, Alp Aydin 1283 MSci <sup>75</sup>, David J Baker BEng <sup>75</sup>, Dr Ebenezer Foster-Nyarko PhD <sup>75</sup>, Dr Sophie J Prosolek 1284 PhD <sup>75</sup>, Steven Rudder <sup>75</sup>, Chris Baxter BSc <sup>77</sup>, Sílvia F Carvalho MSc <sup>77</sup>, Dr Deborah Lavin 1285 PhD <sup>77</sup>, Dr Arun Mariappan PhD <sup>77</sup>, Dr Clara Radulescu PhD <sup>77</sup>, Dr Aditi Singh PhD <sup>77</sup>, Miao 1286 Tang MD <sup>77</sup>, Helen Morcrette BSc <sup>79</sup>, Nadua Bayzid BSc <sup>96</sup>, Marius Cotic MSc <sup>96</sup>, Dr Carlos E 1287 Balcazar PhD<sup>104</sup>, Dr Michael D Gallagher PhD<sup>104</sup>, Dr Daniel Maloney PhD<sup>104</sup>, Thomas D 1288 Stanton BSc <sup>104</sup>, Dr Kathleen A Williamson PhD <sup>104</sup>, Dr Robin Manley PhD <sup>105</sup>, Michelle L 1289 Michelsen BSc <sup>105</sup>, Dr Christine M Sambles PhD <sup>105</sup>, Dr David J Studholme PhD <sup>105</sup>, Joanna 1290 Warwick-Dugdale BSc <sup>105</sup>, Richard Eccles MSc <sup>107</sup>, Matthew Gemmell MSc <sup>107</sup>, Dr Richard 1291 Gregory PhD<sup>107</sup>, Dr Margaret Hughes PhD<sup>107</sup>, Charlotte Nelson MSc<sup>107</sup>, Dr Lucille Rainbow 1292

PhD <sup>107</sup>, Dr Edith E Vamos PhD <sup>107</sup>, Hermione J Webster BSc <sup>107</sup>, Dr Mark Whitehead PhD 1293 <sup>107</sup>, Claudia Wierzbicki BSc <sup>107</sup>, Dr Adrienn Angyal PhD <sup>109</sup>, Dr Luke R Green PhD <sup>109</sup>, Dr Max 1294 Whiteley PhD <sup>109</sup>, Emma Betteridge BSc <sup>116</sup>, Dr Iraad F Bronner PhD <sup>116</sup>, Ben W Farr BSc <sup>116</sup>, 1295 Scott Goodwin MSc <sup>116</sup>, Dr Stefanie V Lensing PhD <sup>116</sup>, Shane A McCarthy <sup>116, 102</sup>, Dr Michael 1296 A Quail PhD <sup>116</sup>, Diana Rajan MSc <sup>116</sup>, Dr Nicholas M Redshaw PhD <sup>116</sup>, Carol Scott <sup>116</sup>, 1297 Lesley Shirley MSc <sup>116</sup> and Scott AJ Thurston BSc <sup>116</sup> 1298

1299

1300 Software and analysis tools:

Dr Will Rowe PhD<sup>43</sup>, Amy Gaskin MSc <sup>74</sup>, Dr Thanh Le-Viet PhD <sup>75</sup>, James Bonfield BSc <sup>116</sup>, 1301 Jennifier Liddle <sup>116</sup> and Andrew Whitwham BSc <sup>116</sup> 1302

1303

1304 1 Barking, Havering and Redbridge University Hospitals NHS Trust, 2 Barts Health NHS Trust, 3 1305 Belfast Health & Social Care Trust, 4 Betsi Cadwaladr University Health Board, 5 Big Data Institute, 1306 Nuffield Department of Medicine, University of Oxford, 6 Blackpool Teaching Hospitals NHS 1307 Foundation Trust, 7 Bournemouth University, 8 Cambridge Stem Cell Institute, University of 1308 Cambridge, 9 Cambridge University Hospitals NHS Foundation Trust, 10 Cardiff and Vale University 1309 Health Board, 11 Cardiff University, 12 Centre for Clinical Infection and Diagnostics Research, 1310 Department of Infectious Diseases, Guy's and St Thomas' NHS Foundation Trust, 13 Centre for 1311 Enzyme Innovation, University of Portsmouth, 14 Centre for Genomic Pathogen Surveillance, 1312 University of Oxford, 15 Clinical Microbiology Department, Queens Medical Centre, Nottingham 1313 University Hospitals NHS Trust, 16 Clinical Microbiology, University Hospitals of Leicester NHS Trust, 1314 17 County Durham and Darlington NHS Foundation Trust, 18 Deep Seg, School of Life Sciences, 1315 Queens Medical Centre, University of Nottingham, 19 Department of Infectious Diseases and 1316 Microbiology, Cambridge University Hospitals NHS Foundation Trust, 20 Department of Medicine, 1317 University of Cambridge, 21 Department of Microbiology, Kettering General Hospital, 22 Department 1318 of Microbiology, South West London Pathology, 23 Department of Zoology, University of Oxford, 24 1319 Division of Virology, Department of Pathology, University of Cambridge, 25 East Kent Hospitals 1320 University NHS Foundation Trust, 26 East Suffolk and North Essex NHS Foundation Trust, 27 East 1321 Sussex Healthcare NHS Trust, 28 Gateshead Health NHS Foundation Trust, 29 Great Ormond Street 1322 Hospital for Children NHS Foundation Trust, 30 Great Ormond Street Institute of Child Health (GOS 1323 ICH), University College London (UCL), 31 Guy's and St. Thomas' Biomedical Research Centre, 32 1324 Guy's and St. Thomas' NHS Foundation Trust, 33 Hampshire Hospitals NHS Foundation Trust, 34 1325 Health Services Laboratories, 35 Heartlands Hospital, Birmingham, 36 Hub for Biotechnology in the 1326 Built Environment, Northumbria University, 37 Hull University Teaching Hospitals NHS Trust, 38 1327 Imperial College Healthcare NHS Trust, 39 Imperial College London, 40 Infection Care Group, St 1328 George's University Hospitals NHS Foundation Trust, 41 Institute for Infection and Immunity, St 1329 George's University of London, 42 Institute of Biodiversity, Animal Health & Comparative Medicine, 43 1330 Institute of Microbiology and Infection, University of Birmingham, 44 Isle of Wight NHS Trust, 45 1331 King's College Hospital NHS Foundation Trust, 46 King's College London, 47 Liverpool Clinical 1332 Laboratories, 48 Maidstone and Tunbridge Wells NHS Trust, 49 Manchester University NHS 1333 Foundation Trust, 50 Microbiology Department, Buckinghamshire Healthcare NHS Trust, 51 1334 Microbiology, Royal Oldham Hospital, 52 MRC Biostatistics Unit, University of Cambridge, 53 MRC-1335 University of Glasgow Centre for Virus Research, 54 Newcastle University, 55 NHS Greater Glasgow 1336 and Clyde, 56 NHS Lothian, 57 NIHR Health Protection Research Unit in HCAI and AMR, Imperial 1337 College London, 58 Norfolk and Norwich University Hospitals NHS Foundation Trust, 59 Norfolk 1338 County Council, 60 North Cumbria Integrated Care NHS Foundation Trust, 61 North Middlesex 1339 University Hospital NHS Trust, 62 North Tees and Hartlepool NHS Foundation Trust, 63 North West 1340 London Pathology, 64 Northumbria Healthcare NHS Foundation Trust, 65 Northumbria University, 66 1341 NU-OMICS, Northumbria University, 67 Path Links, Northern Lincolnshire and Goole NHS Foundation 1342 Trust, 68 Portsmouth Hospitals University NHS Trust, 69 Public Health Agency, Northern Ireland, 70 1343 Public Health England, 71 Public Health England, Cambridge, 72 Public Health England, Colindale,

1344 73 Public Health Scotland, 74 Public Health Wales, 75 Quadram Institute Bioscience, 76 Queen 1345 Elizabeth Hospital, Birmingham, 77 Queen's University Belfast, 78 Royal Brompton and Harefield 1346 Hospitals, 79 Royal Devon and Exeter NHS Foundation Trust, 80 Royal Free London NHS 1347 Foundation Trust, 81 School of Biological Sciences, University of Portsmouth, 82 School of Health 1348 Sciences, University of Southampton, 83 School of Medicine, University of Southampton, 84 School of 1349 Pharmacy & Biomedical Sciences, University of Portsmouth, 85 Sheffield Teaching Hospitals NHS 1350 Foundation Trust, 86 South Tees Hospitals NHS Foundation Trust, 87 Southwest Pathology Services, 1351 88 Swansea University, 89 The Newcastle upon Tyne Hospitals NHS Foundation Trust, 90 The 1352 Queen Elizabeth Hospital King's Lynn NHS Foundation Trust, 91 The Royal Marsden NHS 1353 Foundation Trust, 92 The Royal Wolverhampton NHS Trust, 93 Turnkey Laboratory, University of 1354 Birmingham, 94 University College London Division of Infection and Immunity, 95 University College 1355 London Hospital Advanced Pathogen Diagnostics Unit, 96 University College London Hospitals NHS 1356 Foundation Trust, 97 University Hospital Southampton NHS Foundation Trust, 98 University Hospitals 1357 Dorset NHS Foundation Trust, 99 University Hospitals Sussex NHS Foundation Trust, 100 University 1358 of Birmingham, 101 University of Brighton, 102 University of Cambridge, 103 University of East 1359 Anglia, 104 University of Edinburgh, 105 University of Exeter, 106 University of Kent, 107 University of 1360 Liverpool, 108 University of Oxford, 109 University of Sheffield, 110 University of Southampton, 111 1361 University of St Andrews, 112 Viapath, Guy's and St Thomas' NHS Foundation Trust, and King's 1362 College Hospital NHS Foundation Trust, 113 Virology, School of Life Sciences, Queens Medical 1363 Centre, University of Nottingham, 114 Watford General Hospital, 115 Wellcome Centre for Human 1364 Genetics, Nuffield Department of Medicine, University of Oxford, 116 Wellcome Sanger Institute, 117 1365 West of Scotland Specialist Virology Centre, NHS Greater Glasgow and Clyde, 118 Whittington 1366 Health NHS Trust